Функциональные заболевания органов пищеварения. Синдромы перекреста Клинические рекомендации Российского Научного Медицинского Общества Терапевтов и Научного Общества Гастроэнтерологов России

Функциональные заболевания органов пищеварения, функциональная изжога, функциональная диспепсия, билиарные дисфункции, синдром раздраженного кишечника, синдром перекреста функциональных заболеваний органов пищеварения, overlap- syndrome, функциональная абдоминальная боль, функциональное расстройство, билиарная боль, синдром избыточного бактериального роста, синдром повышенной проницаемости слизистых, синдром повышенной эпителиальной проницаемости

1. Functional Gastroenterology: Assessing and Addressing the Causes of Functional Gastrointestinal Disorders. Paperback by Steven Sandberg- Lewis. March 17, 2017.

2. Drossman D. A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. 2016, Vol. 150, iss. 6, pp. 1262–1279. doi: 10.1053/j.gastro.2016.02.032.

3. Stephen J. Vanner, et al. Fundamentals of Neuro gastroenterology: Basic Science. Gastroenterology. 2016; 150: 1280–1291.

4. Голованова Е. В. Функциональные гастроинтестинальные расстройства: подходы к коррекции психосоматических нарушений. РМЖ. 2019. Т. 27. № 5. С. 24–29.

5. Голованова Е. В. Возможности коррекции функциональных расстройств желудочно- кишечного тракта у пациентов с тревожными расстройствами. РМЖ. 2020. Т. 28. № 6. С. 45–48.

6. Дорофеева Г. Д., Бондарь Л. С., Нофаль Али Нджм. Особенности вегетативного статуса, уровней серотонина и гистамина у детей с синдромом раздраженного кишечника // Український медичний альманах. – 2001. – Т. 4, № 3. – С. 59–62.

7. Андреев Д. Н., Заборовский А. В., Трухманов А. С., Маев И. В., Ивашкин В. Т. Эволюция представлений о функциональных заболеваниях желудочнокишечного тракта в свете Римских критериев IV пересмотра (2016 г.) // РЖГГК. 2017. № 27(1). С. 4–11. ISSN 1382–4376. doi:10.22416/1382–4376–2017–27–1–4–11.

8. Ткач С. М. Римские критерии IV функциональных гастроинтестинальных расстройств: что нового в последней версии // Сучасна гастроентерологія. 2016. № 4(90). С. 116–122.

9. Holtmann G, Talley NJ, Liebregts T et al. A PlaceboControlled Trial of Itopride in Functional Dyspepsia. NEJM. 2006; 23 (354): 832–40.

10. Кляритська І. Л., Курченко М. Г. Сучасні підходи до лі ку вання синдрому роз’ятрених кишок // Нова медицина. – 2003. – № 6. – С. 34–37.

11. Бархатова В. П., Завалишин И. А. Нейротрансмитте рная организация двигательных систем головного и спинного мозга в норме и патологии // Журн. невропатол. и психиатрии. 2004. № 8. С. 77–80.

12. Маев И. В., Черемушкин С. В. Синдром раздраженного кишечника. Римские критерии III // Гастроэнте ро логия. Приложение к Consilium medicum. 2007. Т. 9, № 1. С. 11.

13. Баранская Е. К. Синдром раздраженного кишечника: диагностика и лечение // Consilium medicum. 2002. Т. 4, № 9.

14. Brian E. Lacy, et al. Bowel Disorders. Gastroenterology. 2016;150:1393–1407.

15. Tack J. et al. Functional Gastroduodenal Disorders. Gastroenterology. 2006;130:1466–1479.

16. Drossman D.A., Quigley E. M. Th e global perspective on irritable bowel syndrome: a Rome FoundationWorld Gastroenterology Organisation symposium. Am. J. Gastroenterol. 2012;107 (11):1602–1609. doi: 10.1038/ajg.2012.106.

17. Wouters M.M., Vicario M., Santos J. Th e role of mast cells in functional GI disorders. Gut. 2015, No. 65, pp. 155–168. doi: 10.1136/gutjnl-2015–309151

18. Ивашкин В. Т., Маев И. В., Шульпекова Ю. О., Баран ская Е. К., Охлобыстин А. В., Трухманов А. С., Лапина Т. Л., Шептулин А. А. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению дискинезии желчевыводящих путей. Рос журн гастроэнтерол гепатол колопроктол 2018; 28(3): 63–80.

19. Ami D. Sperber, Shrikant I. Bangdiwala, Douglas A. Drossman, Uday C. Ghoshal, Magnus Simren, Jan Tack, William E. Whitehead, Dan L. Dumitrascu, Xuicai Fang, Shin Fukudo, John Kellow, Edith Okeke, Eamonn M. M. Quigley, Max Schmulson, Peter Whorwell, Timothy Archampong, PaymanAdibi, Viola Andresen, Marc A. Benninga, Bruno Bonaz, Serhat Bor, Luis Bustos Fernandez, SuckChei Choi, Enrico S. Corazziari, Carlos Francisconi, Albis Hani, Leonid Lazebnik, YeongYeh Lee, Agata Mulak, M. Masudur Rahman, Javier Santos, Mashiko Setshedi, Ari Fahrial Syam, Stephen Vanner, Reuben K. Wong, Aurelio Lopez- Colombo, Valeria Costa, Ram Dickman, Motoyori Kanazawa, Ammar Hassanzadeh Keshteli, Rutaba Khatun, Iradj Maleki, Pierre Poitras, Nitesh Pratap, Oksana Stefanyuk, Sandie Thomson, Judith Zeevenhooven, Olafur S. Palsson; Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. V. 160, I. 1, P99–114.E3, JAN. 01, 2021. doi: 10.1053/j.gastro.2020.04.014.

20. Hunt R., Quigley E. et al. WGO Global Guideline – Coping with common GI symptoms in the community. World Gastroenterology Organization. 2013, pp. 1–37.

21. Пиманов С. И., Сливончик Н. Н. Римские IV рекомендации по диагностике и лечению функциональных гастроэнтерологических расстройств. Пособие для врачей. – М., 2016. – 160 с.

22. Coloproctology. Clinical guidelines. Yu. A. Shelygin (ed.). Moscow: GEOTAR-Media, 2017. 560 p. (in Russ.) ISBN 978–5–9704–4357–6 (in Russ.). Колопроктология. Клинические рекомендации / Ю. А. Шелыгин (ред.). – Москва: ГЭОТАР-Медиа, 2017. – 560 с. – ISBN 978–5–9704–4357–6.

23. Ивашкин В. Т., Шелыгин Ю. А., Баранская Е. К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(5):76–93.

24. Ивашкин В. Т., Маев И. В., Шептулин А. А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(1):50–61.

25. Алексеенко С. А., Багдасарян А. А., Бакулин И. Г., и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико- санитарной помощи. Пособие для врачей- терапевтов / Москва, 2019.

26. Лазебник Л. Б., Туркина С. В., Ардатская М. Д., Остроумова О. Д., Голованова Е. В., Комиссаренко И. А., Корочанская Н. В., Козлова И. В., Успенский Ю. П., Фоминых Ю. А., Левченко С. В., Лоранская И. Д., Тка ченко Е. И., Ситкин С. И., Бакулин И. Г., Ба ку лина Н. В., Шемеровский К. А. Клинические рекомендации: запоры у взрослых. Терапия. 2020. Т. 6. № 4 (38). С. 77–101.

27. Лазебник Л. Б., Сарсенбаева А. С., Авалуева Е. Б., Ореш ко Л. С., Ситкин С. И., Голованова Е. В., Туркина С. В., Хлынова О. В., Сагалова О. И., Ми рончев О. В. Клинические рекомендации «Хронические диареи у взрослых». Экспериментальная и клиническая гастроэнтерология. 2021;188(4): 7–67. DOI: 10.31146/1682–8658-ecg-188–4–7–67.

28. World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics’. 2017 Feb. Available at: http:// www.worldgastroenterology.org/guidelines/globalguidelines/probiotics-and-prebiotics/probiotics-andprebiotics- english [Accessed 23 December 2020].

29. Дробижев М. Ю., Федотова А. В., Кикта С. В. Рациональный выбор препарата на основе представлений о патогенезе психического расстройства и механизме его действия // Журнал неврологии и психиатрии им. С. С. Корсакова. 2014. № 11. С. 15–21.

30. Aziz Q., Fass R., Gyawali Prakash C., et al. Esophageal disorders. Gastroenterology. 2016; 150:1368–79.

31. Dickman R, Maradey- Romero C, Fass R. Th e role of pain modulators in esophageal disorders – no pain no gain. Neurogastroenterol Motil. 2014;26:603–610.

32. Bruley des Varanness S, Shi G, Scarpignato C, Galmiche JP. Sensitivity to acid and distension in gastro oesophageal refl ux disease (GORD) and the acid hypersensitive oesophagus. Gut. 1996;39(suppl 3): A182.

33. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62:591–599.

34. Jang SH, Ryu HS, Choi SC, Lee SY. Psychological factors infl uence the overlap syndrome in functional gastrointestinal disorders and their eff ect on quality of life among fi refi ghters in South Korea. J Dig Dis. 2016;17:236–243.

35. Nikaki K, Woodland P, Lee C, et al. Esophageal mucosal innervation in functional heartburn: Closer to healthy asymptomatic subjects than to non-erosive refl ux disease patients. Neurogastroenterol Motil. 2019;31: e13667.

36. Freede M, Leasure AR, Proskin HM, et al. Comparison of Rectal and Esophageal Sensitivity in Women With Functional Heartburn. Gastroenterol Nurs. 2016;39:348–58.

37. De Bortoli N, Frazzoni L, Savarino EV, et al. Functional Heartburn Overlaps With Irritable Bowel Syndrome More Oft en than GERD. Am J Gastroenterol. 2016; 111:- 1711–1717.

38. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive refl ux disease (NERD)—acid refl ux and symptom patterns. Aliment Pharmacol Th er 2003;17:537–545.

39. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neuro gastroenterol Motil. 2017;23(2):151–163. doi: 10.5056/jnm16214

40. Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profi les predict response to proton pump inhibitors in gastro- oesophageal refl ux disease. Gut. 2012;61:501–506.

41. Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med 2019;381:1513–1523.

42. Yamasaki T, Fass R. Refl ux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil. 2017;23:495–503.

43. Savarino E, Marabotto E, Zentilin P, et al. Th e added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive refl ux disease. Dig Liver Dis. 2011;43:542–547.

44. Patel A, Sayuk GS, Gyawali CP. Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring. Neurogastroenterol Motil. 2016;28:1382–1390.

45. Roman S, Keefer L, Imam H, et al. Majority of symptoms in esophageal refl ux PPI non-responders are not related to refl ux. Neurogastroenterol Motil. 2015;27:1667–1674.

46. Пережогин Л. О. Соматоформные расстройства. Диагностика, лечение, профилактика. Клинические рекомендации. М., 2015.

47. Broderick R, Fuchs KH, Breithaupt W, et al. Clinical Pre sen tation of Gastroesophageal Refl ux Disease: A Prospec tive Study on Symptom Diversity and Modifi cation of Questionnaire Application. Dig Dis. 2019:1–8.

48. Poh CH, Gasiorowska A, Navarro- Rodriguez T, et al. Upper GI tract fi ndings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antirefl ux treatment. Gastrointest Endosc. 2010;71:28–34.

49. Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal refl ux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.

50. Garcia- Compean D, Gonzalez Gonzalez JA, Marrufo Garcia CA, et al. Prevalence of eosinophilic esophagitis in patients with refractory gastroesophageal refl ux disease symptoms: A prospective study. Dig Liver Dis. 2011;43:204–8.

51. Abe N, Takeuchi H, Ohki A, et al. Long-term outcomes of com bi nation of endoscopic submucosal dissection and laparoscopic lymph node dissection without gastrectomy for early gastric cancer patients who have a potential risk of lymph node metastasis. Gastrointestinal Endoscopy. 2011;74:792–797.

52. Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy- resistant refl ux symptoms: ’on’ or ’off ’ proton pump inhibitor? Am J Gastroenterol. 2008;103:2446– 2453.

53. Pritchett JM, Aslam M, Slaughter JC, et al. Effi cacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal refl ux disease, on and off therapy. Clin Gastroenterol Hepatol. 2009;7:743–748.

54. Dulery C, Lechot A, Roman S, et al. A study with pharyngeal and esophageal 24-hour pH-impedance monitoring in patients with laryngopharyngeal symptoms refractory to proton pump inhibitors. Neurogastroenterol Motil. 2017;29.

55. De Bortoli N, Nacci A, Savarino E, et al. How many cases of laryngopharyngeal refl ux suspected by laryngoscopy are gastroesophageal refl ux disease- related? World J Gastroenterol. 2012;18:4363–4370.

56. Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27(s3):3–7.

57. Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro- oesophageal refl ux for laparoscopic Nissen fundoplication. Br J Surg. 2006; 93:1483–1487.

58. Kahrilas PJ, Bredenoord AJ, Fox M, et al. Th e Chicago Classifi cation of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–174.

59. Josefsson A, Palsson O, Simren M, et al. Oesophageal symptoms are common and associated with other functional gastrointestinal disorders (FGIDs) in an Englishspeaking Western population. United European Gastroenterol J. 2018;6:1461–1469.

60. Myers JP, vom Saal FS, Akingbemi BT, Arizono K, Belcher S, Colborn T, et al. 2009. Why public health agencies cannot depend on Good Laboratory Practices as a criterion for selecting data: the case of bisphenol A. Environ Health Perspect 117:309S315. Environmental Health Perspectives. 2009;117: A482–4.

61. Fass R, Zerbib F, Gyawali CP, AGA Clinical Practi ce Update on Functional Heartburn: Expert Review, Gastroenterology. (2020), doi: 10.1053/j.gastro. 2020.01.034.

62. Fass R, Naliboff BD, Fass SS, et al. Th e eff ect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal refl ux disease. Gastroenterology. 2008;134:696–705.

63. Schey R, Dickman R, Parthasarathy S, et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal refl ux disease. Gastroenterology. 2007;133:1787–1795.

64. Clevers E, Tornblom H, Simren M, et al. Relations between food intake, psychological distress, and gastrointestinal symptoms: a diary study. United European Gastroenterol J. 2019;7:965–973.

65. Gyawali CP, Fass R. Management of gastroesophageal refl ux disease. Gastroenterology. 2018;154:302–318.

66. Doraiswamy PM, Varia I, Hellegers C, et al. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull. 2006;39:15–24.

67. Spinhoven P, Van der Does AJ, Van Dijk E, Van Rood YR. Heart- focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitivebehavioral therapy and paroxetine. J Psychosom Res. 2010;69:227–235.

68. Ostovaneh MR, Saeidi B, Hajifathalian K, et al. Compa ring omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double- blind placebo- controlled trial. Neurogastroenterol Motil. 2014;- 26: 670–678.

69. Abdallah J, George N, Yamasaki T, et al.Most patientswith gastroesophageal refl ux disease who failed proton pump inhibitor therapy also have functional esophageal disorders. Clin Gastroenterol Hepatol. 2019;17:1073–1080 e1.

70. Fass OZ, Fass R. Overlap between GERD and functional esophageal disorders – a pivotal mechanism for treatment failure. Curr TreatOptions Gastroenterol. 2019;17:161–164.

71. Rodriguez- Stanley S, Ciociola AA, Zubaidi S, et al. A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn. Aliment Pharmacol Th er. 2004;20:975–982.

72. Basu P, Hempole H, Krishnaswamy N. The effect of melatonin in functional heartburn: a randomized, placebo- controlled clinical trial. Op J Gastroenterol. 2014; 2014:56–61.

73. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Th er. 2007; 26:1333–1344.

74. Riehl ME, Pandolfi no JE, Palsson OS, et al. Feasibility and acceptability of esophageal- directed hypnotherapy for functional heartburn. Dis Esophagus. 2016; 29:- 490–496.

75. Khajanchee YS, Hong D, Hansen PD, et al. Outcomes of antirefl ux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg. 2004; 187:599–603.

76. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome aft er laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999; 3:- 292–300.

77. Choung RS, Richard Locke G, 3rd, Schleck CD, et al. Multiple functional gastrointestinal disorders linked to gastroesophageal refl ux and somatization: A populationbased study. Neurogastroenterol Motil. 2017;29.

78. Frazzoni M, Savarino E, Manno M, et al. Refl ux patterns in patients with short- segment Barrett’s oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Th er. 2009;30:508–15.

79. Domingues GR, Moraes- Filho JP, Domingues AG. Impact of prolonged 48-h wireless capsule esophageal pH monitoring on diagnosis of gastroesophageal refl ux disease and evaluation of the relationship between symptoms and refl ux episodes. Arq Gastroenterol. 2011;- 48: 24–9.

80. Nojkov B, Rubenstein JH, Adlis SA, et al. Th e infl uence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro- oesophageal refl ux disease. Aliment Pharmacol Th er. 2008;27:473–82.

81. Roman S, Zerbib F, Queneherve L, et al. Th e Chicago classifi cation for achalasia in a French multicentric cohort. Dig Liver Dis. 2012;44:976–80.

82. Шептулин А. А., Кайбышева В. О. Функциональная изжога и гиперчувствительность пищевода к рефлюксу (По материалам Римских критериев функциональных заболеваний пищевода IV пересмотра). Рос журн гастроэнтерол гепатол колопроктол 2017; 27(2):13–18.

83. Colin- Jones DG, Bloom B, Bodemar G et al. Management of dyspepsia: report of a working party. Lancet. 1988; 331: 576–9.

84. Stanghellini V, Chan FKL, Hasler WL et al. Gastro duodenal disorders. Gastroenterology. 2016; 150: 1380–92.

85. ACG and CAG Clinical Guideline: Management of Dyspepsia.Moayyedi, Paul M; Lacy, Brian E; Andrews, Christopher N; Enns, Robert A; Howden, Colin W; Vakil, Nimish American Journal of Gastroenterology: July 2017, Volume 112, Issue 7, pp. 988–1013. doi: 10.1038/ ajg.2017.154

86. Лазебник Л. Б., Алексеенко С. А., Лялюкова Е. А., Сам со нов А. А., Бордин Д. С. и др. Рекомендации по ведению первичных пациентов с симптомами диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018;153(05):04–18.

87. Маев И. В., Драпкина О. М., Лазебник Л. Б. от имени рабочей группы. Положения к алгоритму по ведению первичных необследованных пациентов с симптомами диспепсии на этапе первичной медикосанитарной помощи. Профилактическая медицина. 2019;22(1):35–42. Doi: 10.17116/profmed20192201135.

88. Vanheel H, Farré R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10:142–149.

89. Troncon LE, Bennett RJ, Ahluwalia NK, et al. Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients. Gut. 1994;35:327–332.

90. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115: 1346–1352.

91. Bratten J, Jones MP. Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol. 2009;43:527–533.

92. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853–1863.

93. Gathaiya N, Locke GR 3rd, Camilleri M, et al. Novel associations with dyspepsia: a community- based study of familial aggregation, sleep dysfunction and somatization. Neurogastroenterol Motil. 2009;21:922 e69.

94. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med. 2003; 65:528–533.

95. Koloski NA, Jones M, Talley NJ. Investigating the directionality of the brain gut mechanism in functional gastrointestinal disorders. Gut. 2012;61:1776–1777.

96. Walker MM, Aggarwal KR, Shim LS, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confi rmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014;29:474–479.

97. Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10:168–174.

98. Андреев Д. Н., Маев И. В., Кучерявый Ю. А. Распрост раненность синдрома избыточного бактериального роста в тонкой кишке у пациентов с функциональной диспепсией: метаанализ, Терархив, 2020, № 12,

99. Costa MB, Azeredo IL Jr, Marciano RD, Caldeira LM, Bafutto M. Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test. Arq Gastroenterol. 2012;49(4):279–83. doi: 10.1590/s0004–28032012000400009

100. Ford AC, Marwaha A, Sood R et al. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015; 64: 1049–57.

101. Международная статистическая классификация болезней и проблем, cвязанных со здоровьем. Десятый пересмотр (МКБ-10), 1995;1:579–580.

102. Mearin F, Perez- Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome aft er a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98–104.

103. Cremon C, Stanghellini V, Pallotti F, et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology. 2014;147:69–77.

104. S Stapley,1 T J Peters,2 R D Neal,3 P W Rose,4 F M Walter,5 and W Hamilton6,* Th e risk of oesophago- gastric can cer in symptomatic patients in primary care: a large case–control study using electronic records. Br J Cancer. 2013 Jan 15; 108(1): 25–31.

105. Chen SL, Gwee KA, Lee JS, Miwa H, Suzuki H, Guo P, et al. Systematic review with meta-analysis: prompt endoscopy as the initial management strategy for uninvestigated dyspepsia in Asia. Aliment Pharmacol Th er. 2015;41:239–52.

106. Приказ МЗ РФ № 248 «Об утверждении стандарта медицинской помощи больным хроническим гастритом, дуоденитом, диспепсией» от 22 ноября 2004 г.

107. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liv Dis. 2008;40:650–8. doi: 10.1016/j.dld.2008.02.030

108. Capelle LG, de Vries AC, Haringsma J, et al. Th e staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150–8.doi:10.1016/j. gie.2009.12.029

109. Алгоритм ведения первичных необследованных пациентов с симптомами диспепсии. Приказ МЗ РФ № 17–9/9414 от 18.01.2019 г.

110. Heaney A, Collins JSA, Watson RGP et al. A prospective randomised trial of a “test and treat” policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut. 1999; 45: 186–90.

111. Lassen AT, Pedersen FM, Bytzer P et al. Helicobacter pylori test-anderadicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet. 2000; 356: 455–60.

112. McColl KE, Murray LS, Gillen D et al. Randomised controlled trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ. 2002; 324: 999.

113. Arents NLA, Th ijs JC, van Zwet AA et al. Approach to treatment of dyspepsia in primary care: a randomised trial comparing ‘test and treat’ with prompt endoscopy. Arch Intern Med. 2003; 163: 1606–12

114. Mahadeva S, Chia YC, Vinothini A et al. Cost-eff ectiveness of and satisfaction with a Helicobacter pylori ‘‘test and treat’’ strategy compared with prompt endoscopy in young Asians with dyspepsia. Gut. 2008; 57: 1214–20.

115. Duggan AE, Elliott CA, Miller P et al. Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. Aliment Pharmacol Th er. 2009; 29: 55–68.

116. Chiba N, Veldhuyzen van Zanten SJO, Sinclair P et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment–Helicobacter pylori positive (CADET-HP) randomised controlled trial. BMJ. 2002; 324: 1012–7.

117. Stevens R, Baxter G. Benefi t of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care. Gastroenterology. 2001; 120 (5 Suppl 1): A50

118. Sugano K., Tack J., Kuipers E. J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64:133–67.

119. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2016 Oct 5. doi: 10.1136/gutjnl-2016–312288

120. Meineche- Schmidt V, Krag E. Antisecretory therapy in 1017 patients with ulcerlike or refl ux-like dyspepsia in general practice. Eur J General Pract. 1997; 3: 125–30.

121. Goves J, Oldring JK, Kerr D et al. First line treatment with omeprazole provides an eff ective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Alimen Pharmacol Th er. 1998; 12: 147–57.

122. Rabeneck L, Soucheck J, Wristers K et al. A double blind, randomized, placebo- controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. Am J Gastroenterol. 2002; 97: 3045–51.

123. Meineche- Schmidt V. Empiric treatment with high and standard dose of Omeprazole in General Practice: two-week randomised placebo controlled trial and 12 month follow up of healthcare consumption. Am J Gastroenterol. 2004; 99: 1050–8.

124. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol. 2005; 100: 1477–88.

125. Baysal B, Şentürk H, Masri O et al. Eff ect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. Turk J Gastroenterol. 2015; 26: 6–14.

126. Moayyedi P., Delaney B. C., Vakil N. Th e effi cacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004; 127:1329–37.

127. Tominaga K., Suzuki H., Umegaki E. et al. Rabeprazole imprоves the symptoms of functional dyspepsia – a double- blind randomized placebo- controlled multicenter trial in Japan: Th e CAESAR study. DDW, New Orleans 2010: A383.

128. Blum A, Arnold R, Stolte M et al. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut. 2000; 47: 473–80.

129. Bolling- Sternevald E, Lauritsen K, Aalykke C et al. Eff ect of profound acid suppression in functional dyspepsia: a double- blind, randomized, placebo- controlled trial. Scand J Gastroenterol. 2002; 37: 1395–402.

130. Farup PG, Hovde O, Torp R et al. Patients with functional dyspepsia responding to omeprazole have a characteristic gastro- oesophageal refl ux pattern. Scand J Gastroenterol. 1999; 34: 575–9.

131. Fletcher J, Derakhshan MH, Jones GR et al. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut. 2011; 60: 442–8.

132. Gerson LB, Triadafi lopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis. 2005; 37: 87–91.

133. Iwakiri R, Tominaga K, Furuta K et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Th er. 2013; 38: 729–40.

134. Peura DA, Kovacs TO, Metz DC et al. Lansoprazole in the treatment of functional dyspepsia: two double- blind, randomized, placebo- controlled trials. Am J Med. 2004; 116: 740–8.

135. Suzuki H, Kusunoki H, Kamiya T et al. Eff ect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): a multicentre, prospective, randomized, double- blind, placebo- controlled clinical trial. United Eur Gastroenterol J. 2013; 1: 445–52.

136. Talley NJ, Meineche- Schmidt V, Paré P et al. Effi cacy of omeprazole in functional dyspepsia: double- blind, randomized, placebo- controlled trials (the Bond and Opera studies). Aliment Pharmacol Th er. 1998; 12: 1055–65.

137. Talley NJ, Vakil N, Lauritsen K et al. Randomizedcontrolled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Th er. 2007; 26: 673–82.

138. Van Rensburg C, Berghöfer P, Enns R et al. Effi cacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin. 2008; 24: 2009–18.

139. Van Zanten SV, Armstrong D, Chiba N et al. Eso mepra zole 40 mg once a day in patients with functional dyspepsia: the randomized, placebocontrolled “ENTER” trial. Am J Gastroenterol. 2006; 101: 2096–106.

140. Wong WM, Wong BCY, Hung WK et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut. 2002; 51: 502–6.

141. Hengels KJ. Th erapeutic effi cacy of 15 mg lansoprazole mane in 269 patients suff ering from non-ulcer dyspepsia (NUD): a multicentre, randomised, double- blind study. Gut. 1998; 43 (Suppl 2): A89.

142. Al- Quorain A, Larbi EB, al- Shedoki F. A doubleblind, randomized, placebo- controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol. 1995; 30: 531–4.

143. Champion MC, MacCannell KL, Thomson AB et al. A double- blind randomized study of cisapride in the treatment of nonulcer dyspepsia. Th e Canadian Cisapride Nud Study Group Can J Gastroenterol. 1997; 11: 127–34.

144. Chung JM. Cisapride in chronic dyspepsia: results of a double- blind, placebo- controlled trial. Scand J Gastroenterol Suppl. 1993; 195: 11–14.

145. Erratum in: Scand J Gastroenterol Suppl 1993; 28: 749. Creytens G. Effect of the non-antidopaminergic drug cisapride on postprandial nausea. CurrTherap Res. 1984; 36: 1063–70.

146. De Groot GH, de Both PS. Cisapride in functional dyspepsia in general practice. A placebo- controlled, randomized, double- blind study. Aliment Pharmacol Th er. 1997; 11: 193–9.

147. De Nutte N, Van Ganse W, Witterhulghe M et al. Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Th er. 1989; 11: 62–8.

148. Francois I, De Nutte N. Non-ulcer dyspepsia: eff ect of the gastrointestinal prokinetic drug cisapride. Curr Th er Res. 1987; 41: 891–8.

149. Hallerbäck BI, Bommelaer G, Bredberg E et al. Dose fi nding study of mosapride in functional dyspepsia: a placebo- controlled, randomized study. Aliment Pharmacol Th er. 2002; 16: 959–67.

150. Hannon R. Effi cacy of cisapride in patients with non-ulcer dyspepsia. Curr Th er Res. 1987; 42: 814–22.

151. Hansen JM, Bytzer P, Schaff alitzky de Muckadell OB. Placebo- controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol. 1998; 93: 368–74.

152. Holtmann G, Gschossmann J, Mayr P et al. A randomized placebocontrolled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Th er. 2002; 16: 1641–8.

153. Holtmann G, Talley NJ, Liebregts T et al. A placebocontrolled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354: 832–40.

154. Kellow JE, Cowan H, Shuter B et al. Effi cacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Th er. 1995; 9: 153–60.

155. Matsueda K, Hongo M, Tack J et al. Clinical trial: dose-dependent therapeutic effi cacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia-100 mg tid is an optimal dosage. Neurogastroenterol Motil. 2010; 22: 618 – e173.

156. Matsueda K, Hongo M, Tack J et al. A placebo- controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012; 61: 821–8.

157. Miwa H, Nagahara A, Tominaga K et al. Effi cacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009; 104: 2779–87.

158. Rösch W. Cisapride in non-ulcer dyspepsia. Results of a placebo- controlled trial. Scand J Gastroenterol. 1987; 22: 161–4.

159. Talley NJ, Verlinden M, Snape W et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized doubleblind placebo- controlled trial. Aliment Pharmacol Th er. 2000; 14: 1653–61.

160. Talley NJ, Van Zanten SV, Saez LR et al. A dose-ranging, placebo- controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Th er. 2001; 15: 525–37.

161. Talley NJ, Tack J, Ptak T et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double- blind, placebo- controlled trials. Gut. 2008; 57: 740–6.

162. Vakil N, Laine L, Talley NJ et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008; 103: 1906–19.

163. Wood SF, Penney SC, Cochran KM. Cisapride in functional dyspepsia: a double- blind, placebo- controlled randomized trial in general practice patients. Scand J Gastroenterol Suppl. 1993; 195: 5–10.

164. Yeoh KG, Kang JY, Tay HH et al. Eff ect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double- blind placebocontrolled trial. J Gastroenterol Hepatol. 1997; 12: 13–8.

165. Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J. 1979; 55 (Suppl 1): 30–2.

166. Chey WY, You CH, Ange DA. Open and double blind clinical trials of domperidone in patients with unexplained nausea, vomiting, abdominal bloating and early satiety. Gastroenterology. 1982; 82 (Suppl 1): 1033.

167. Davis RH, Clench MH, Mathias JR. Eff ects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a doubleblind placebo- controlled study. Dig Dis Sci. 1988; 33: 1505–11.

168. Haarmann K, Lebkuchner F, Widmann A et al. A double- blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress. Postgrad Med J. 1979; 55 (suppl 1): 24–7.

169. Van de Mierop L, Rutgeerts L, Van den Langenbergh B et al. Oral domperidone in chronic postprandial dyspepsia. Digestion. 1979; 19: 244–50.

170. Van Ganse W, Van Damme L, Van de Mierop L et al. Chronic dyspepsia: double- blind treatment with domperidone (R 33 812) or a placebo. A multicentre therapeutic evaluation. Curr Th erap Res. 1978; 23: 695–702.

171. Van Outryve M, Lauwers W, Verbeke S. Domperidone for the symptomatic treatment of chronic post-prandial nausea and vomiting. Postgrad Med J. 1979; 55 (suppl 1): 33–5.

172. Lacy BE, Talley NJ, Locke GR et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Th erap. 2012; 36: 3–15.

173. Th élin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Th er. 2020 Feb;51(4):421–434. doi: 10.1111/ apt.15611. Epub 2020 Jan 17. PMID: 31950535.

174. Лазебник Л. Б. Полиморбидность у пожилых. Сердце. 2007; 7: 25–7. /

175. Силивончик Н. Н. Цитопротекция желудочнокишечного тракта. Семейный доктор –2018 г. № 3. С. 9–13.

176. Мараховский Ю. Х., Адаменко Е. И., Жарская О. М., Ка ра сева Г. А. Уточнение эффективности комбинации гвайазулена с диметиконом при диспепсии на основе самооценки пациентами «Рецепт», 2019, том 22, № 2, С 192–213.

177. Faser A. Th e Short- Form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Th er. 2007. vol. 15, pp. 477–486.

178. Яковенко Э. П., Иванов А. Н., Агафонова Н. А., Яковенко А. В., Прянишникова А. С. Лечение больных неэрозивной рефлюксной болезнью. Лечащий врач. 2012; (7): 131–134.

179. WHO ATC – A03AX Other drugs for functional gastrointestinal disorders. https://www. whocc.no/atc_ ddd_index

180. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67(9):667–70.

181. Tan VP, Liu KS, Lam FY, Hung IF, Yuen MF, Leung WK. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Th er. 2017;45(6):767–776. doi: 10.1111/apt.13945.

182. Th élin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Th er. 2020 Feb;51(4):421–434. doi: 10.1111/ apt.15611. Epub 2020 Jan 17. PMID: 31950535.

183. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut- Brain Interaction. Gastroenterology. 2016;150(6):1257–61.

184. Маев И. В., Черёмушкин С. В., Кучерявый Ю. А., Черёмушкина Н. В. Синдром раздраженного кишечника. Римские критерии IV. Consilium Medicum. 2016; 18(8): 79–85.

185. Waehrens R, Li X, Sundquist J, et al. Perinatal and fami lial risk factors for irritable bowel syndrome in a Swedish national cohort. Scand J Gastroenterol. 2018;53(5):559–566.

186. Zamani M, Alizadeh- Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Th er. 2019;50(2):132–143.

187. Törnblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what’s the link? Am J Gastroenterol. 2012;107(5):754–60.

188. Mertz H., Naliboff B., Munakata J., Niazi N., Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995; 109: 40–52.

189. Carco C, Young W, Gearry RB, Talley NJ, McNabb WC, Roy NC. Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis. Front Cell Infect Microbiol. 2020 Sep 9;10:468. doi: 10.3389/ fcimb.2020.00468

190. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62 (1):159–176. doi: 10.1136/gutjnl-2012–302167

191. Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. Th e Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Th erapy. Front Microbiol. 2019 Jun 10;10:1136. doi: 10.3389/fmicb.2019.01136

192. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014 Jul 21;20(27):8859–66. doi: 10.3748/ wjg.v20.i27.8859

193. Shukla R, Ghoshal U, Ranjan P, Ghoshal UC. Expression of Toll-like Receptors, Pro-, and Anti-infl ammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: Th e Evidence for Its Micro-organic Basis. J Neurogastroenterol Motil. 2018 Oct 1;24(4):628– 642. doi: 10.5056/jnm18130

194. Liebregts T. et al., Immuneactivation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132(3):913–920. PubMed: 17383420.

195. Akiho H. et al. Low-grade infl ammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010; 1(3):97–105. PubMed: 21607147.

196. Van Sommeren S. et al. HNF4alpha and CDH1 are associated with ulcerative colitis in a Dutch cohort. Infl amm Bowel Dis. 2011; 17(8):1714–1718. PubMed: 21744425.

197. Ahn SH. et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against infl ammatory bowel disease. Infl amm. Bowel Dis. 2008; 14(7):908–920. PubMed: 18338782.

198. Babeu JP, Darsigny M, Lussier CR, Boudreau F. Hepatocyte nuclear factor 4alpha contributes to an intestinal epithelialphenotype in vitro and plays a partial role in mouse intestinal epithelium diff erentiation. Am J Physiol GastrointestLiver Physiol. 2009; 297: G124-G134. PMID: 19389805. DOI: 10.1152/ajpgi.90690.2008

199. Cattin AL, Le Beyec J, Barreau F, Saint- Just S, Houllier A, Gonzalez FJ, Robine S, Pinçon- Raymond M, Cardot P, Lacasa M, Ribeiro A. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol Cell Biol. 2009; 29: 6294–6308. PMID: 19805521 DOI: 10.1128/MCB.00939–09

200. Lussier CR, Babeu JP, Auclair BA, Perreault N, Boudreau F. Hepatocyte nuclear factor-4alpha promotes diff erentiation of intestinal epithelial cells in a coculture system. Am J. Physiol Gastrointest Liver Physiol. 2008; 294: G418-G428. PMID: 18032476. DOI: 10.1152/ ajpgi.00418.2007

201. Archer A, Sauvaget D, Chauffeton V, Bouchet PE, Chambaz J, Pinçon- Raymond M, Cardot P, Ribeiro A, Lacasa M. Intestinal apolipoprotein A-IV gene transcription is controlled by two hormone- responsive elements: a role for hepatic nuclear factor-4 isoforms. Mol Endocrinol. 2005; 19: 2320–2334. PMID: 15928313.

202. Stegmann A, Hansen M, Wang Y, Larsen JB, Lund LR, Ritié L, Nicholson JK, Quistorff B, Simon- Assmann P, Troelsen JT, Olsen J. Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte diff erentiation. Physiol. Genomics. 2006; 27: 141–155. PMID: 16868071. DOI: 10.1152/physiolgenomics.00314.2005

203. Chiba H, Gotoh T, Kojima T, Satohisa S, Kikuchi K, Osanai M, Sawada N. Hepatocyte nuclear factor (HNF)- 4alpha triggers formation of functional tight junctions and establishment of polarized epithelial morphology in F9 embryonal carcinoma cells. Exp Cell Res. 2003; 286: 288–297. PMID: 12749857 DOI: 10.1016/S0014– 4827(03)00116–2

204. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, Duncan SA. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci USA. 2006; 103: 8419–8424. PMID: 16714383. DOI: 10.1073/pnas.0600246103

205. Ситкин C. И. Воспаление, микробиота, висцеральная гиперчувствительность – новые и «старые» терапевтические мишени при синдроме раздраженного кишечника. Клинические перспективы гастроэнтерологии, гепатологии. 2014; (3): 43–52.

206. Philpott H, Gibson P, Thien F. Irritable bowel syndrome –An infl ammatory disease involving mast cells. Asia Pac Allergy. 2011 Apr;1(1):36–42. doi: 10.5415/ apallergy.2011.1.1.36

207. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. Th e microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013 Jun;18(6):666–673. doi: 10.1038/mp.2012.77

208. Duan R, Zhu S, Wang B, Duan L. Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review. Clin Transl Gastroenterol. 2019 Feb;10(2): e00012. doi: 10.14309/ctg.0000000000000012

209. Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut Microbiota in Patients With Irritable Bowel Syndrome- A Systematic Review. Gastroenterology. 2019 Jul;157(1):97–108. doi: 10.1053/j. gastro.2019.03.049

210. Wang L, Alammar N, Singh R, Nanavati J, Song Y, Chaudhary R, Mullin GE. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta- Analysis of Case- Control Studies. J Acad Nutr Diet. 2020 Apr;120(4):565–586. doi: 10.1016/j. jand.2019.05.015

211. Shin A, Preidis GA, Shulman R, Kashyap PC. The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders. Clin Gastroenterol Hepatol. 2019 Jan;17(2):256–274. doi: 10.1016/j.cgh.2018.08.054

212. Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The Microbiome and Irritable Bowel Syndrome –A Review on the Pathophysiology, Current Research and Future Th erapy. Front Microbiol. 2019 Jun 10;10:1136. doi: 10.3389/fmicb.2019.01136

213. Mari A, Abu Baker F, Mahamid M, Sbeit W, Khoury T. Th e Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020 Mar 4;9(3):685. doi: 10.3390/jcm9030685

214. Tap J, Derrien M, Törnblom H, Brazeilles R, CoolsPortier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M. Identifi cation of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology. 2017 Jan;152(1):111–123. e8. doi: 10.1053/j.gastro.2016.09.049

215. Mars RAT, Yang Y, Ward T, et al. Longitudinal Multiomics Reveals Subset- Specifi c Mechanisms Underlying Irritable Bowel Syndrome. Cell. 2020 Sep 17;182(6):1460– 1473.e17. doi: 10.1016/j.cell.2020.08.007

216. Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):28–35. doi: 10.1097/ MED.0000000000000523

217. Rodiño- Janeiro BK, Vicario M, Alonso- Cotoner C, PascuaGarcía R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Th erapies. Adv Th er. 2018 Mar;35(3):289–310. doi: 10.1007/s12325–018–0673–5

218. R. Spiller, Ch. Lam. An update on post-infectious irritable bowel syndrome. J Neurogastroenterol Motil, Vol.18, № 3, 2012.

219. Talley NJ, Weaver A, Zinsmeister AR, Melton LJ., 3rd Onset and disappearence of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol. 1992;136(2):165–177.

220. Agreus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general popu la ti on: overlap and lack of stability over time. Gastroenterology. 1995;109(3):671–680.

221. Locke GR, 3rd, Yawn BP, Wollan PC, Melton LJ, 3rd, Lydick E, Talley NJ. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. Aliment Pharmacol Th er.2004;19(9):1025–1031.

222. Lovell RM, Ford AC. Eff ect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991–1000.

223. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut. 1997;41(3):394–398.

224. Chang SY, Jones MP. Consulters and nonconsulters in irritable bowel syndrome: what makes an IBS patient? Pract Gastroenterol. 2003;6:15–26.

225. Hungin AP, Whorwell PJ, Tack J, Mearin F. Th e prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Th er. 2003;17(5):643–650.

226. Canavan C, West J, Card T. Th e epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014; 6: 71–80.

227. Hillilä MT, Siivola MT, Färkkilä MA. Comorbidity and use of healthcare services among irritable bowel syndrome suff erers. Scand J Gastroenterol. 2007;42(7):799–806.

228. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology.2002;122(4):1140–1156.

229. Aggarwal VR, McBeth J, Zakrzewska JM, Lunt M, Macfarlane GJ. Th e epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol.2006;35(2):468–476.

230. Lackner JM, Ma CX, Keefer L, et al. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(9):- 1147–1157.

231. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004;126(7):1665–1673.

232. Chang JY, Locke GR, 3rd, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822–832.

233. Black TP, Manolakis CS, Di Palma JA. “Red fl ag” evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis. 2012;21(2):153–156.

234. World Gastroenterology Organization. Global Guideline. Irritable bowel syndrome: a global perspective. 2009.

235. Hod K, Dickman R, Sperber A, et al. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome. Neurogastroenterol Motil. 2011;23(12):1105–1110.

236. Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude infl ammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–454.

237. Von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical diff erentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97–103.

238. Jonefj äll B, Öhman L, Simrén M, et al. IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological wellbeing. Infl amm Bowel Dis. 2016; 22:2630–2640.

239. Ishihara S, Yashima K, Kushiyama Y, et al. Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multicenter study utilizing colonoscopy. J Gastroenterol. 2012;47(10):1084–1090.

240. Gu HX, Zhang YL, Zhi FC, Jiang B, Huang Y. Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case–control study. Int J Colorectal Dis. 2011;26(7):935–940.

241. Porter CK, Cash BD, Pimentel M, Akinseye A, Riddle MS. Risk of infl ammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 2012;12:55.

242. García Rodríguez LA, Ruigómez A, Wallander MA, Johansson S, Olbe L. Detection of colorectal tumor and infl ammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2000;35(3):306–311.

243. Алексеева О. П., Касимова Л. Н., Горячева Е. Е. Привер женность к терапии у пациентов с патологией желудочно- кишечного тракта. Рос. журн. гастроэнтерол. гепатол. колопроктол. 2016; 26(1):20–28.

244. Hajizadeh Maleki B, Tartibian B, Mooren FC, et al. Lowto-moderate intensity aerobic exercise training modulates irritable bowel syndrome through antioxidative and infl ammatory mechanisms in women: Results of a randomized controlled trial. Cytokine. 2018; 102:18–25.

245. Zhou C, Zhao E, Li Y, et al. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterol Motil. 2019;31(2): e13461.

246. Ostgaard H, Hausken T, Gundersen D, El- Salhy M. Diet and eff ects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Rep. 2012;5:1382–1390.

247. Корниенко Е. А. Нецелиакийная чувствительность к глютену. Экспериментальная и клиническая гастроэнтерология, 2017; 139(3):89–98.

248. Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016;55(3):897–906.

249. Chang, L., Lembo, A., Sultan, S. American Gastroentero logical Association technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014; 147: 1149–1172.

250. Ford AC, Talley NJ, Spiegel BM, Foxx- Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Eff ect of fi bre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337: a2313.

251. Xie C., Tang Y., Wang Y., Yu T., Wang Y., Jiang L., Lin L. Effi cacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A MetaAnalysis. PLoS One. 2015 Aug 7; 10(8): e0127815.eCollection 2015.

252. Ruepert L., Quartero A. O., van der Heijden G. J., et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10; (8): CD003460.

253. Ford A.C., Moayyedi P., Lacy B. E. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109 (Suppl 1): S2–26.

254. Chang F.Y., Lu C. L., Chen C. Y., Luo J. C. Effi cacy of dioctahedral smectite in treating patients of diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007; 22(12):2266–72.

255. Menees S.B., Maneerattannaporn M., Kim H. M., Chey W. D. Th e effi cacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and metaanalysis. Am J Gastroenterol. 2012 Jan; 107(1):28–35.

256. Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal infl ammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571–575. doi: 10.4161/gmic.32130.

257. Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, doubleblind, placebo- controlled trials. Aliment Pharmacol Th er. 2014;39:1161–8.

258. Pimentel M, Lembo A, Chey WD, et al. Engl J Med. 2011;364(1):22–32.

259. Lin H. C. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004, Vol. 292, pp. 852–858.

260. Di Stefano M., Strocchi A. S., Malservisi S. et al. Nonabsorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment. Pharmacol. Th er. 2000, Vol. 14, pp. 1001–1008.

261. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is eff ective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Th er. 2017;45(5):604–616.

262. Lorenzo- Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome- related quality of life. World J Gastroenterol. 2014 Jul 14;20(26):8709– 8716. doi: 10.3748/wjg.v20.i26.8709

263. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Ra stall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616. doi: 10.1038/s41575–019–0173–3

264. Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, Li Y. Eff ects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016 Jun 13;16(1):62. doi: 10.1186/s12876–016–0470-z

265. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the effi cacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Th er. 2018 Nov;48(10):1044–1060. doi: 10.1111/apt.15001

266. Barraza- Ortiz DA, Pérez- López N, Medina- López VM, Minero- Alfaro JI, Zamarripa- Dorsey F, FernándezMartínez NDC, Llorente- Ramón A, Ramos- Aguilar GA. Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study. Dig Dis. 2020 Aug 18. doi: 10.1159/000510950

267. Lorén V, Manyé J, Fuentes MC, Cabré E, Ojanguren I, Espadaler J. Comparative Eff ect of the I3.1 Probiotic Formula in Two Animal Models of Colitis. Probiotics Antimicrob Proteins. 2017 Mar;9(1):71–80. doi: 10.1007/ s12602–016–9239–5

268. Perez M, Astó E, Huedo P, Alcántara C, Buj D, Espadaler J. Derived Postbiotics of a Multi‐strain Probiotic Formula Clinically Validated for the Treatment of Irritable Bowel Syndrome. FASEB J. 2020;34(S1):1–1. doi:10.1096/fasebj.2020.34.s1.05062

269. Cano- Contreras AD, Minero Alfaro IJ, Medina López VM, Amieva Balmori M, Remes Troche JM, Espadaler Mazo J, Perez Lopez N. Efficacy of i3.1 Probiotic on Improvement of Lactose Intolerance Symptoms: A Randomized, Placebo- controlled Clinical Trial. J Clin Gastroenterol. 2020 Oct 29. doi: 10.1097/ MCG.0000000000001456

270. Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019 Apr;2(1):6–29. doi: 10.1093/jcag/gwy071

271. Ивашкин В. Т., Маев И. В., Абдулганиева Д. И., и соавт. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков для лечения и профилактики заболеваний гастроэнтерологического профиля у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):76–89. DOI: 10.22416/1382–4376–2020–30–2–76–89.

272. Finney M, Smullen J, Foster HA, Brokx S, Storey DM. Eff ects of low doses of lactitol on faecal microfl ora, pH, short chain fatty acids and gastrointestinal symptomology. Eur J Nutr. 2007 Sep;46(6):307–314. doi: 10.1007/ s00394–007–0666–7

273. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: Th e International Scientifi c Association for Probiotics and Prebiotics (ISAPP) consensus statement on the defi nition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491–502. doi: 10.1038/nrgastro.2017.75

274. Azpiroz F, Dubray C, Bernalier- Donadille A, Cardot JM, Accarino A, Serra J, Wagner A, Respondek F, Da poigny M. Eff ects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study. Neurogastroenterol Motil. 2017 Feb;29(2). doi: 10.1111/nmo.12911

275. Seung- Hee Lee et al. Identifi cation of Alverine and Benfl uorex as HNF4α Activators. ACS Chem. Biol. 2013, 8, 8, 1730–1736 Publication Date: May 15, 2013. Doi: 10.1021/cb4000986

276. J.-Ph. Babeu, Fr. Boudreau. Hepatocyte nuclear factor 4-alpha involvement in liver and intestinal infl ammatory networks. WJG20th Anniversary Special Issues (3): Infl ammatory bowel disease. World J Gastroenterol. 2014 January 7; 20(1):22–30. doi: 10.3748/wjg.v20.i1.22

277. Bueno L, Beaufrand C, Th eodorou V, Andro- Delestrain MC. Infl uence of simethicone and alverine on stressinduced alterations of colonic permeability and sensitivity in rats: benefi cial eff ect of their association. J Pharm Pharmacol. 2013 Apr;65(4):567–73. doi: 10.1111/ jphp.12021

278. Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Clinical trial: the effi cacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome – a randomized, double- blind, placebo- controlled study. Aliment Pharmacol Th er. 2010 Mar;31(6):615–624. doi: 10.1111/j.1365–2036.2009.04216.x

279. Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O’Ma hony V, Andro- Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014 Feb;68(2):245–254. doi: 10.1111/ijcp.12333

280. Ткаченко Е. И., Авалуева Е. Б., Ситкин С. И., Жигалова Т. Н., Сказываева Е. В., Миргородская Е. В., Петренко В. В. Интестинальная двигательная активность у пациентов с синдромом раздраженного кишечника. Гастроэнтерология Санкт- Петербурга. 2008;(4):7–10.

281. Маев И. В., Черемушкин С. В., Кучерявый Ю. А., Черемушкина Н. В., Баркова Т. В. Многоцелевая терапия синдрома раздраженного кишечника: современный взгляд на решение проблемы. Фарматека, 2015, 10 (303), С. 20–25.

282. Ottillinger B., Storr M., Malfertheiner P., Allescher H. D. STW 5 (Iberogast.)–a safe and eff ective standard in the treatment of functional gastrointestinal disorders. Wien Med Wschr. 2013 Feb; 163(3–4):65–72.

283. Андреев Д. Н., Кучерявый Ю. А., Черемушкин С. В., Маев И. В. Эффективность включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника: метаанализ контролируемых исследований. Consilium Medicum. 2020, (22);8. DOI: 10.26442/20751753.2020.8.200194.

284. Маев И. В., Черёмушкин С. В., Кучерявый Ю. А., Черёмушкина Н. В. Алгоритм ведения пациентов с синдромом раздраженного кишечника. Римские критерии IV. РМЖ. 2017; 10: 718–722.

285. Cotton P.B., Elta G. H., Carter C. R., Pasricha P. J., Corazziari E. S. Rome IV. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology. 2016. 150:1420–1429. e2.doi: 10.1053/j.gastro.2016.02.033

286. Elham Afghani, Simon K. Lo, Paul S. Covington, Brooks D. Cash, Stephen J. Pandol. Sphincter of Oddi Function and Risk Factors for Dysfunction.

287. Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional gallbladder and sphincter of Oddi disorders. Gastroenterology. 2006;130:1498–509. Doi: 10.1053/j.gastro.2005.11.063

288. Hall TC, Dennison AR, Garcea G. The diagnosis and management of Sphincter of Oddi dysfunction: a systematic review. Langenbecks Arch Surg. 2012 Aug;397(6):889–98. doi: 10.1007/s00423–012–0971–3. Epub 2012 Jun 13. PMID: 22688754.

289. Ильченко А. А. Болезни желчного пузыря и желчных путей. 2-е изд., перераб и доп. М.: Медицинское информационное агентство; 2011. 880 с.

290. Лейшнер У. Практическое руководство по заболеваниям желчных путей. М.: ГЭОТАР-МЕД; 2001. 264 с.

291. Ивашкин, В. Т. Гастроэнтерология. Национальное руководство / под ред. В. Т. Ивашкина, Т. Л. Лапиной– Москва: ГЭОТАР-Медиа, 2018. 464c.

292. Goussous N, Kowdley GC, Sardana N, Spiegler E, Cunningham SC. Gallbladder dysfunction: how much longer will it be controversial? Digestion. 2014;90(3):147–54.

293. Костюкевич О. И., Былова Н. А., Симбирцева А. С. Роль кишечной микробиоты в развитии заболеваний печени и желчевыводящих путей. РМЖ. 2016; № 11: с. 713–720. URL: https://www.rmj.ru/articles/ gastroenterologiya/Roly_kishechnoy_mikrobioty_v_ razvitii_zabol.

294. Amaral J., Xiao Z. L., Chen Q., Yu P., Biancani P., Behar J. Gallbladder muscle dysfunction in patients with chronic acalculous disease. Gastroenterology. 2001;120(2):506–511. doi: 10.1053/gast.2001.21190

295. Bonfrate L., Wang D. Q., Garruti G., Portincasa P. Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract. Res. Clin. Gastroenterol. 2014;28(4):623–635. DOI: 10.1016/j.bpg.2014.07.013

296. Chávez- Talavera O., Tailleux A., Lefebvre P., Staels B. Bile Acid Control of Metabolism and Infl ammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017;152(7):1679–94.e3. Doi: 10.1053/j.g

297. Jaruvongvanich V., Sanguankeo A., Upala S. Signifi cant Asso ci ation Between Gallstone Disease and Non alcoholic Fatty Liver Disease: A Systematic Review and MetaAnalysis. Dig Dis Sci. 2016;61(8):2389–2396. doi: 10.1007/s10620–016–4125–2

298. Liew P.L., Lee W. J., Wang W., Lee Y. C., Chen W. Y., Fang C. L., Huang M. T. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18(7):847–853. doi: 10.1007/s11695–007–9355–0

299. Loria P., Lonardo A., Lombardini S., Carulli L., Verrone A., Ganazzi D. et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J. Gastroenterol. Hepatol. 2005;20(8):1176–1184. doi: 10.1111/j.1440–1746.2005.03

300. Yener O., Aksoy F., Demır M., Özçelık A., Erengül C. Gallstones associated with nonalcoholic steatohepatitis (NASH) and metabolic syndrome. Turk. J. Gastroenterol. 2010;21(4):411–415. doi: 10.4318/ tjg.2010.0128

301. Chen L.Y., Qiao Q. H., Zhang S. C., Chen Y. H., Chao G. Q., Fang L. Z. Metabolic syndrome and gallstone disease. World J. Gastroenterol. 2012;18(31):4215– 4220. doi: 10.3748/wjg.v18.i31.4215

302. Méndez- Sánchez N., Chavez- Tapia N.C., Motola- Kuba D., Sanchez- Lara K., Ponciano- Rodríguez G., Baptista H. et al. Metabolic syndrome as a risk factor for gallstone disease. World J. Gastroenterol. 2005;11(11):1653–1657. doi: 10.3748/wjg.v11.i11.1

303. Alcon S., Morales S., Camello P. J., Pozo M. J. Contribution of diff erent phospholipases and arachidonic acid metabolites in the response of gallbladder smooth muscle to cholecystokinin. Biochem. Pharmacol. 2002;64(7):1157– 1167. doi: 10.1016/s0006

304. Lee Y.S., Kang B. K., Hwang I. K., Kim J., Hwang J. H. Long- term Outcomes of Symptomatic Gallbladder Sludge. Journal of clinical gastroenterology. 2015;49(7):594–598. doi: 10.1097/MCG.0000000000000202

305. Pozo M.J., Camello P. J., Mawe G. M. Chemical mediators of gallbladder dysmotility. Curr. Med. Chem. 2004;11(13):1801–1812. doi: 10.2174/0929867043364955

306. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569–80.

307. Toouli J. Th e sphincter of Oddi and acute pancreatitis– revisited. HPB. 2003;5(3):142–5.

308. Chen TS. (2018) Sphincter of Oddi Dysfunction. In: Lai KH., Mo LR., Wang HP. (eds) Biliopancreatic Endoscopy. Springer, Singapore. doi: 10.1007/978–981–10– 4367–3

309. Ponchon T, Aucia N, Mitchell R, Chavaillon A, Bory R, Hedelius F. Biopsies of the ampullary region in patients suspected to have sphincter of Oddi dysfunction. Gastrointest Endosc. 1995; 42:296–300. [AN 96121318].

310. Черногорова М. В. Функциональные билиарные расстройства и постхолецистэктомический синдром. Учебное пособие для врачей / М. В. Черногорова, Е. А. Белоусова, М. Б. Долгова, Е. А. Медведева; ГБУЗ МО МОНИКИ им. М. Ф. Владимирского. – М. 2019:40с.

311. Kaw M, Brodmerkel GJ Jr. ERCP, biliary crystal analysis, and sphincter of Oddi manometry in idiopathic recurrent pancreatitis. Gastrointest Endosc. 2002;55(2):157–62.

312. Eversman D, Fogel EL, Rusche M, Sherman S, Lehman GA. Frequency of abnormal pancreatic and biliary sphincter manometry compared with clinical suspicion of sphincter of Oddi dysfunction. Gastrointest Endosc. 1999;50:637–41. doi:10.1016/S0016–5107(99)

313. Coyle WJ, Pineau BC, Tarnasky PR, et al. Evaluation of unexplained acute and acute recurrent pancreatitis using endoscopic retrograde cholangiopancreatography, sphincter of Oddi manometry and endoscopic ultrasound. Endoscopy. 2002;34(8):617–23.

314. Peloponissios N, Gillet M, Cavin R, Halkic N. Agenesis of the gallbladder: a dangerously misdiagnosed malformation. World J Gastroenterol. 2005;11:6228–31. doi:10.3748/wjg.v11.i39.6228

315. Wehrmann T, Lembcke B, Caspary WF, Seifert H. Sphincter of Oddi dysfunction aft er successful gallstone lithotripsy (postlithotripsy syndrome): manometric data and results of endoscopic sphincterotomy. Dig Dis Sci. 1999; 44:2244–50. doi:10.1023/A

316. Clavien PA, Camargo CA Jr, Baillie J, Fitz JG. Sphincter of Oddi dysfunction aft er liver transplantation. Dig Dis Sci. 1995; 40:73–4. doi:10.1007/BF02063944

317. Lai KH, Lo GH, Cheng JS, Fu MT, Wang EM, Chan HH, et al. Eff ect of somatostatin on the sphincter of Oddi in patients with acute non–biliary pancreatitis. Gut. 2001; 49:843–6. doi:10.1136/gut.49.6.843

318. Inkinen J, Sand J, Arvola P, Porsti I, Nordback I. Direct eff ect of thyroxine on pig sphincter of Oddi contractility. Dig Dis Sci. 2001; 46:182–6. doi:10.1023/A:1005674211976

319. Laukkarinen J, Sand J, Saaristo R, Salmi J, Turjanmaa V, Vehkalahti P, et al. Is bile fl ow reduced in patients with hypothyroidism? Surgery. 2003; 133:288–93. doi:10.1067/ msy.2003.77

320. Völzke H, Robinson DM, John U. Association between thyroid function and gallstone disease. World J Gastroenterol. 2005; 11:5530–4. doi:10.3748/wjg.v11.i35.5530

321. George J, Baillie J. Biliary and gallbladder dyskinesia. Curr Treat Options Gastroenterol. 2007; 10:322–7. doi:10.1007/s11938–007–0075–2

322. Ozden N., DiBaise J. K. Gallbladder ejection fraction and symptom outcome in patients with acalculous biliary-like pain. Dig. Dis. Sci. 2003;48:890–897.

323. Hyun JJ, Kozarek RA. Sphincter of Oddi dysfunction: sphincter of Oddi dysfunction or discordance? What is the state of the art in 2018? Curr Opin Gastroenterol. 2018 Sep;34(5):282–287. doi: 10.1097/ MOG.0000000000000455. PMID: 29916850.

324. DiBaise JK, Oleynikov D. Does gallbladder ejection fraction predict outcome aft er cholecystectomy for suspected chronic acalculous gallbladder dysfunction? A systematic review. Am J Gastroenterol. 2003; 98:2605– 11. 10.1111/j.1572–0241.2003.08772.x

325. Laugier R, Grandval P, Ville E. Dysfonction du sphincter d’Oddi [Dysfunction of the Oddi’s sphincter]. Gastroenterol Clin Biol. 2001 Sep;25(2 Pt 2): C24–9. French. PMID: 11787376.

326. Lee Y.S., Kang B. K., Hwang I. K., Kim J., Hwang J. H. Long-term Outcomes of Symptomatic Gallbladder Sludge. Journal of clinical gastroenterology. 2015;49(7):594–598. doi: 10.1097/MCG.0000000000000202

327. Gleeson FC, Levy MJ. Endoscopic ultrasound (EUS) guided access and therapy of pancreatico–biliary disorders. Minerva Gastroenterol Dietol. 2008 Jun;54(2):151– 60. PMID: 18319688.

328. Shami VM, Kahaleh M. Endoscopic ultrasonography (EUS)–guided access and therapy of pancreatico–biliary disorders: EUS–guided cholangio and pancreatic drainage. Gastrointest Endosc Clin N Am. 2007 Jul;17(3):581–93, vii–viii. doi: 10.1016/j.giec.2

329. Chavalitdhamrong D, Draganov PV. Endoscopic ultrasound–guided biliary drainage. World J Gastroenterol. 2012 Feb 14;18(6):491–7. doi: 10.3748/wjg.v18.i6.491. PMID: 22363114; PMCID: PMC3280393.

330. Lim CH, Jahansouz C, Freeman ML, Leslie DB, Ikramuddin S, Amateau SK. Outcomes of Endoscopic Retrograde Cholangiopancreatography (ERCP) and Sphincterotomy for Suspected Sphincter of Oddi Dysfunction (SOD) Post Roux–En–Y Gastric Bypass. Obes Surg. 20.

331. Yaghoobi M, Pauls Q, Durkalski V, Romagnuolo J, Fogel EL, Tarnasky PR, Aliperti G, Freeman ML, Kozarek RA, Jamidar PA, Wilcox CM, Elta GH, Hawes RH, Wood–Williams A, Cotton PB. Incidence and predictors of post–ERCP pancreatitis in patients with susp.

332. Miyatani H, Matsumoto S, Mashima H. Risk factors of post–endoscopic retrograde cholangiopancreatography pancreatitis in biliary type sphincter of Oddi dysfunction in Japanese patients. J Dig Dis. 2017 Oct;18(10):591– 597. doi: 10.1111/1751–2980.1254

333. Delgado–Aros S, Cremonini F, Bredenoord AJ, Camilleri M. Systematic review and meta–analysis: does gall–bladder ejection fraction on cholecystokinin cholescintigraphy predict outcome aft er cholecystectomy in suspected functional biliary pain? Aliment.

334. Miyatani H, Mashima H, Sekine M, Matsumoto S. Clinical course of biliary–type sphincter of Oddi dysfunction: endoscopic sphincterotomy and functional dyspepsia as aff ecting factors. Th er Adv Gastrointest Endosc. 2019;12:2631774519867184.

335. Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. Th e irritable sphincter. Dig Dis Sci. 1995; 40: 1149–1156.

336. De Vries DR, Van Herwaarden MA, Baron A, et al. Concomitant functional dyspepsia and irritable bowel syndrome decrease health–related quality of life in gastroesophageal refl ux disease. Scand J Gastroenterol. 2007; 42: 951–956.

337. Evans PR, Bak YT, Dowsett JF, Smith RC, Kellow JE. Small bowel dysmotility in patients with postcholecystectomy sphincter of Oddi dysfunction. Dig Dis Sci. 1997 Jul;42(7):1507–12. doi: 10.1023/a:1018879029855. PMID: 9246055.

338. Ros E, Zambon D. Postcholecystectomy symptoms. A prospective study of gallstone patients before and two years aft er surgery. Gut. 1987;28:1500–4.

339. Burns DG. Th e risk of abdominal surgery in irritable bowel syndrome. S Afr Med J. 1986;70:91.

340. McNally MA, Locke GR, Zinsmeister AR, Schleck CD, Peterson J, Talley NJ. Biliary events and an increased risk of new onset irritable bowel syndrome: a population- based cohort study. Aliment Pharmacol Th er. 2008;28(3):334–343. doi:10.1111/j

341. Kamath PS, Gaisano HY, Phillips SF, Miller LJ, Charboneau JW, Brown ML, et al. Abnormal gallbladder motility in irritable bowel syndrome: evidence for target- organ defect. Am J Physiol. 1991;260(6 Pt 1): G815–9.

342. Saito YA, Schoenfeld P, Locke GR., III Th e epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–15.

343. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Th er. 2005;21(11):1365–75.

344. Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen V, Hamm LR, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Th er. 2005;22(10):935–42.

345. Bennett E, Evans P, Dowsett J, et al. Sphincter of Oddi dysfunction: psychosocial distress correlates with manometric dyskinesia but not stenosis. World J Gastroenterol. 2009; 15: 6080–6085.

346. Preece JD, Davies IH, Wilkinson SP. Use of the SeHCAT test in the investigation of diarrhoea. Postgrad Med J. 1992;68(798):272–6.

347. Schiller LR, Hogan RB, Morawski SG, Santa Ana CA, Bern MJ, Norgaard RP, et al. Studies of the prevalence and signifi cance of radiolabeled bile acid malabsorption in a group of patients with idiopathic chronic diarrhea. Gastroenterology. 1987;92.

348. Suhr O, Danielsson A, Nyhlin H, Truedsson H. Bile acid malabsorption demonstrated by SeHCAT in chronic diarrhoea, with special reference to the impact of cholecystectomy. Scand J Gastroenterol. 1988;23(10):1187–94.

349. Sand J, Nordback I, Koskinen M, Matikainen M, Lindholm TS. Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol. 1993 Apr;88(4):530–5.

350. Khuroo MS, Zargar SA, Yattoo GN. Effi cacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double- blind, randomized, placebo- controlled, cross over trial. Br J Clin Pharmacol. 1992;33:477–485.

351. Насонова С. В., Цветкова Л. И. Опыт применения Одестона в лечении хронических заболеваний желчного пузыря и желчевыводящих путей. Россий ский журнал гастроэнтерологии, гепатологии, колопроктологии. 2000; № 3: с. 87–90.

352. Abate A., Dimartino V., Spina P., Costa P. L., Lom bardo C., Santini A. et al. Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, doubleblind, placebo- controlled clinical study. Drugs Exp Clin Res. 2001;27(5–6):223–225.

353. Garrett ER, Venitz J. Comparisons of detections, stabilities, and kinetics of degradation of hymecromone and its glucuronide and sulfate metabolites. Journal of pharmaceutical sciences. 1994;83(1):115–6.

354. Hoff mann RM, Schwarz G, Pohl C, Ziegenhagen DJ, Kruis W. Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility. Deutsche medizinische Wochenschrift. 2005;130(34– 35):1938–1946.

355. Rodriguez T.S. et al. Choleretic activity and biliary elimination of lipids and bile acids induced by an artichoke leaf extract in rats. Phytomedicine. 2002; 9:687–693.

356. Яковенко Э. П., Агафонова Н. А., Яковенко А. В., Иванов А. Н., Каграманова А. В. Агонист опиатных рецепторов тримебутин в терапии функциональных расстрой ств желчного пузыря и сфинктера Одди. Лечащий врач. 2014; № 2: с. 1–4.

357. Волынец Г. В., Хавкин А. И. Урсодезоксихолевая кислота и болезни печени. Ж. Лечащий врач, 2020 июнь;6.

358. Симаненков В. И., Саблин О. А., Лутаенко Е. А., Ильчишина Т. А. Возможности применения урсодеоксихолевой кислоты (препарата «Урдокса») при дискинезиях желчевыводящих путей. Гастроэнтерология Санкт- Петербурга. 2010; № 2–3: с. 23–26.

359. Bundy R., Walker A. F., Middleton R. W. Artichoke leaf extract (Cynarascolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. 2008;15:668–75.

360. Foster J. Clinical uses of artichoke leaf extract. Am. J. Health- Syst.Pharm. 2007;64:35–50.

361. Hempfling W., Dilger K., Beuers U. Systematic review: ursodeoxycholic acid-adverse eff ects and drug interactions. Aliment. Pharmacol. Ther. 2003 Nov. 15;18(10):963–72.

362. Маев И. В., Вьючнова Е. С., Левченко О. Б. Дисфункция билиарного тракта: от патогенеза к выбору оптимальной терапии. РМЖ. 2011; № 28: с. 1736–1741.

363. May G.R., Sutherlandt L. R., Shaff er E. A. Effi cacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. Aliment. Pharmacol.Th er. 1993; 7: 139–148.

364. Realini S., Reiner M., Frigerio G. Treatment of dyspeptic disorders, lithiasis and biliary dyskinesia with ursodeoxycholic acid. Analysis of a controlled multicenter study. Schweiz. Med. Wochenschr. 1980 May 31;110(22):879–80.

365. Sharma B.C., Agarwal D. K., Dhiman R. K., et al. Bile lithogenicity and gallbladder emptying in patients with microlithiasis: eff ect of bile acid therapy. Gastroenterology. 1998;115:124–128.

366. Alvisi V., Tralli M., Loponte A., D’Ambrosi A., Pavani F., Ruina M. Ursodeoxycholic acid in the treatment of dyspeptic- painful disorders of biliary origin: report of a controlled multicenter study. Clin. Ter. 1982. Jan. 15;100(1):21–33.

367. Kirchhoff R. et al. Increase in choleresis by means of artichoke extract. Results of randomized placebоcontrolled double- blind study. Phytomedicine. 1994; 1(2): 107–115.

368. Carr J.A., Walls J., Bryan L. J., et al. Th e treatment of gall- bladder dyskinesia based upon symptoms: results of a 2- year, prospective, nonrandomized, concurrent cohort study. Surg. Laparosc. Endosc. Percutan. Tech. 2009; 19:222–226.

369. Preston J.F., Diggs B. S., Dolan J. P., et al. Biliary dyskinesia: a surgical disease rarely found outside the United States. Am. J. Surg. 2015;209:799–803.

370. Veenstra B.R., Deal R. A., Redondo R. E., et al. Longterm efficacy of laparoscopic cholecystectomy for the treatment of biliary dyskinesia. Am. J. Surg. 2014;207:366–370.

371. Bielefeldt K., Saligram S., Zickmund S. L., Dudekula A., Olyaee M., Yadav D. Cholecystectomy for biliary dyskinesia: how did we get there? Dig. Dis. Sci. 2014;59:2850–2863.

372. Иванченкова Р. А. Хронические заболевания желчевыводящих путей. М.: Издательство «Атмосфера», 2006; 416 с.

373. Лебедева О. В., Буеверов А. О., Буеверова Е. Л., Никитина Л. О. Влияние холецистэктомии в молодом возрасте на течение метаболического синдрома у женщин. Альманах клинической медицины. 2017; № 45(5): с. 384–391. doi: 10.18786/2072–0505–2017– 45–5–384–39.

374. Nervi F., Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am. J. Gastroenterol. 2013;108(6):959–961. doi: 10.1038/ ajg.2013.84

375. Ruhl C.E., Everhart J. E. Relationship of nonalcoholic fatty liver disease with cholecystectomy in the US population. Am. J. Gastroenterol. 2013;108(6):952–958. doi: 10.1038/ajg.2013.70

376. Fracanzani A.L., Valenti L., Russello M., Miele L., Bertelli C., Bellia A. et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One. 2012;7(7): e41183. doi: 10.1371/journal

377. Li ZH, Chen M, Liu JK, Ding J, Dong JH. Endoscopic sphincterotomy in the treatment of cholangiopancreatic diseases. World J Gastroenterol. 2005;11(17):2678–2680. doi:10.3748/wjg.v11.i17.2678

378. Nychytaĭlo MIu, Ohorodnyk PV, Deĭnychenko AH, Leonenko SN. [Diagnosis and endoscopic treatment of stenosing papillitis]. Klin Khir. 2008 Sep;(9):10–3. Ukrainian. PMID: 19275027.

379. Freeman ML, Gill M, Overby C, Cen YY. Predictors of outcomes after biliary and pancreatic sphincterotomy for sphincter of oddi dysfunction. J Clin Gastroenterol. 2007 Jan;41(1):94–102. doi: 10.1097/01. mcg.0000225584.40212.fb . PMID: 17198071.

380. Саидмурадова А., Мансурова Ф. Непосредственные и отдаленные последствия эндоскопической папиллосфинктеротомии у больных желчнокаменной болезнью. Клин Мед. М. 2005;83(9):38–40. PMID: 16279038.

381. Drossman DA. Th e functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130:1377–90.

382. Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, Sperber AD. Gender, age, society, culture, and the patient’s perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130:1435–46.

383. Costanza CD, Longstreth GF, Liu AL. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol. 2004; 2: 395–9.

384. Drossman DA. Chronic functional abdominal pain. Am J Gastroenterol. 1996;91:2270–82. 385. Greenbaum DS, Greenbaum RB, Joseph JG, Natale JE. Chronic abdominal wall pain. Diagnostic validity and costs. Dig Dis Sci. 1994;39:1935–41.

385. Bharucha AE, Camilleri M. Functional abdominal pain in the elderly. Gastroenterol Clin North Am. 2001;30:517–29.

386. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, FunchJensen P, Corazziari E. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–80.

387. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 2000.

388. Clouse RE, Mayer EA, Aziz Q, Drossman DA, Dumi trascu DL, MЪnnikes H, Naliboff BD. Functional abdominal pain syndrome. Gastroenterology. 2006; 130: 1492–7.

389. Sperber AD, Drossman DA. Review article: the functional abdominal pain syndrome. Aliment Pharmacol Th er. 2011;33:514–24.

390. Клинические рекомендации РГА по лечению пациентов с абдоминальной болью. http://www.gastro.ru/ userfi les/R_AB_2015_4.pdf

391. Jackson J.L. et al., 2000, Ruepert L, Quarttero AO. Bulking agents, antispasmodics and antidepressants for the treatment or irritable bowel syndrome. Intervention review. Th e Cochraine Library. 2011, Issue 8.

392. Пизова Н. В. Инсомния у лиц пожилого возраста. Медицинский совет. № 17, 2016. 34–37.

393. Лукушкина, Е. Ф. Карпович Е. И., Чабан О. Д. Аминофенил масляная кислота (Анвифен): клиникофармакологические аспекты и опыт применения в детской неврологии. РМЖ. – 2014 № 3, 3–6.

394. Вальдман А. В., Воронина Т. А. Фармакология ноотропов. М., 1989: 26–35.

395. Воронина Т. А., Середенин С. Б. Ноотропные пре па раты, достижения и новые проблемы. Экспериментальная и клиническая фармакология, 1998, 61(4): 3–9.

396. Евтушенко И. С. Ноотропы и нейропротекторы в современной клинической нейрофармакологии. Международный неврологический журнал, 2013, 3: 57.

397. Мехилане, Л.С., Васар В. Э. Спектр клинического действия фенибута. Ученые записки Тартуского государственного университета. Выпуск 687. Механизмы действия и клиника производных гамма- аминомасляной кислоты. Труды по медицине. Тарту. Типография ТГУ. – 1984. – с. 112–124.

398. Дробижев М. Ю., Федотова А. В., Кикта С. В. Лечение астении. Можно ли предложить что-то новое? // РМЖ. 2017. № 9. С. 1–5.

399. Дробижев М. Ю., Федотова А. В., Кикта С. В., Антохин E. Ю. Феномен аминофенилмасляной кислоты // РМЖ. 2016. № 17. С. 1–7.

400. Owen D.R., Wood D. M., Archer J. R.H., Dar gan P. I. Phenibut (4-amino-3-phenyl- butyric acid): Availability, prevalence of use, desired eff ects and acute toxicity. Drug Alcohol Rev. 2015. DOI: 10.1111/dar.12356

401. Samokhvalov A.V., Paton- Gay C.L., Balchand K., Rehm J. Phenibut dependence. BMJ Case Rep. 2013. DOI: 10.1136/bcr-2012–008381

402. Wong A., Little M., Caldicott D. et al. Analytically confi rmed recreational use of Phenibut (β-phenyl-γ-aminobutyric acid) bought over the internet. Clinical Toxicology. 2015. Vol. 53(7). P. 783–784.

403. Magsalin R.M., Khan A. Y. Withdrawal symptoms aft er Internet purchase of phenibut (β-phenyl-γ-aminobutyric acid HCl). J Clin Psychopharmacol. 2010. Vol. 30(5). P. 648–649.

404. Зоркин С. Н., Борисова С. А., Гусарова Т. Н. Расстройства мочеиспускания у детей. Роль врача амбулаторной практики // Практика педиатра. 2008. Интернет- ресурс: http://medi.ru/doc/j0108018.htm

405. Горина А. С., Goetze S., Колесниченко Л. С. Во зрастная динамика моноаминергических нейротрансмиттеров в спинномозговой жидкости при аутизме, синдроме дефицита внимания и гиперактивности и их коморбидности // Сибирский медицинский журнал. 2013. № 2. С. 34–37.

406. Осадчук М. А., Cвистунов А. А., Киреева Н. В., Осад чук М. М. Функциональные заболевания желудочно- кишечного тракта в контексте синдрома перекреста: современное состояние проблемы. Терапевтический архив. 2020; 92 (2): 112–118. doi: 10. 26442/00403660.2020.02.000458

407. Оганов Р. Г. Симаненков В. И. Бакулин И.Г и соавт. Коморбидная патология в клинической пра ктике. Алгоритмы диагностики и лечения. Кардио васкулярная терапия и профилактика. 2019;18(1):5–66. doi: 10.15829/1728–8800–2019–1–5–66

408. Talley NJ. What Causes Functional Gastrointestinal Disorders? A Proposed Disease Model. Am J Gastroenterol. 2020 Jan;115(1):41–48. doi:10.14309/ ajg.0000000000000485

409. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712–721.e4. doi: 10.1016/j.cgh.2012.02.029

410. Eusebi LH, Ratnakumaran R, Bazzoli F, Ford AC. Prevalence of Dyspepsia in Individuals With Gastroesophageal Refl ux- Type Symptoms in the Community: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018; 16 (1): 39–48. doi: 10.1016/j. cgh.2017.07.041

411. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010; 8 (5): 401–9. doi: 10.1016/j. cgh.2009.07.020

412. Yi ZH, Yang ZB, Kang L, Feng L, Yang L. Clinical features, quality of life and psychological health of patients with irritable bowel syndrome and functional dyspepsia. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 May;45(3):493–6.Chinese.

413. Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health- related quality of life. J Gastroenterol Hepatol. 2010;25(6):1151–6. doi: 10.1111/j.1440–1746.2010.06249

414. Цуканов В. В., Васютин А. В., Тонких Ю. Л., Ржа виче ва О. С., Буторин Н. Н., Перетятько О. В. Синдром перекреста ГЭРБ и диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018;154 (6): 36–39.

415. Vakil N, Stelwagon M, Shea E, Miller S. Symptom burden and consult- ing behavior in patients with overlapping functional disorders in the US population. Unit Eur Gastroenterol J. 2015;4(3):413–22. doi: 10.1177/2050640615600114

416. Вялов С. С. Overlap- синдром функциональных нарушений: факторы риска и обоснование лечения. Consilium Medicum. 2018; 20 (12): 117–121. doi: 10.264 42/20751753.2018.12.180083

417. De Bortoli N, Tolone S, Frazzoni M et al. Gastroesophageal refl ux disease, functional dys- pepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018; 31 (6): 639–48. doi: 10.20524/aog.2018.0314

418. Rasmussen S, Jensen TH, Henriksen SL et al. Overlap of symptoms of gastroesophageal refl ux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015; 50 (2): 162–9. doi: 10.3109/00365521.2014.983157

419. Полунина Т. Е. Синдром раздраженного кишечника и патология билиарного тракта. Клинический разбор. Медицинский совет. 2020;(15):28–38. doi: 10.21518/2079–701X-2020–15–28–38.

420. Морозова М. А., Рупчев Г. Е., Алексеев А. А., Бениашвили А. Г., Маевская М. В., Полуэктова Е. А. и др. Ди сфо рический спектр эмоциональных расстройств у больных с синдромом раздраженного ки шеч ника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):12–22. doi: 10.22416/1382–4376–2017–27–1–12–22.

421. Talley NJ. Functional dyspepsia: advances in diagnosis and therapy. Gut Liver. 2017;11(3): 349–57. doi: 10.5009/ gnl16055

422. Пасечников ВД, Голубь ИВ. Исследование моторики желудка у больных с синдромом перекреста гастроэзофагеальной рефлюксной болезни и функциональной диспепсии. Альманах клинической медицины. 2017;45(5):377–83. doi: 10.18786/2072– 0505–2017–45–5–377–383

423. Holtmann G, Shah A, Morrison M. Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Dig Dis. 2017;35 Suppl 1:5–13.doi: 10.1159/000485409

424. Shin A, Preidis GA, Shulman R, Kashyap PC. The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders. Clin Gastroenterol Hepatol. 2019 Jan;17(2):256–274. doi: 10.1016/j.cgh.2018.08.054

425. Barko PC, McMichael MA, Swanson KS, Williams DA. Th e Gastrointestinal Microbiome: A Review. J Vet Intern Med. 2018 Jan;32(1):9–25. doi:10.1111/jvim.14875

426. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita ÅV, Pardon N, Santos J, Söderholm JD, Tack J, Farré R. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014 Feb;63(2):262–71. doi: 10.1136/gutjnl-2012–303857

427. Schmulson M, Bielsa MV, Carmona- Sánchez R, Hernández A, López- Colombo A, López Vidal Y, PeláezLuna M, Remes- Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade infl ammation, and antibiotic therapy in irritable bowel syndrome: an evidence- based review. Rev Gastroenterol Mex. 2014 Apr- Jun;79(2):96–134. English, Spanish. doi:10.1016/j.rgmx.2014.01.004

428. Chin VK, Yong VC, Chong PP, Amin Nordin S, Basir R, Abdullah M. Mycrobiome in the Gut: A Multiperspective Review. Mediators Inflamm. 2020;2020:9560684. Published 2020 Apr doi:10.1155/2020/9560684

429. Самсонов А. А., Караулов С. А., Ульянкина Е. В., Яшина А. В. Перекрест клинических симптомов функциональной диспепсии и синдрома раздраженного кишечника, их динамика на фоне комбинированной терапии прокинетиками и пробиотиками. Consilium Medicum. 2015; 17 (8): 51–54.

430. Barbara G, Feinle- Bisset C, Ghoshal U, Santos J, Vanner S, Vergnolle N, et al. Th e Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016;150(6):1305–18. doi: 10. 1053/j.gastro.2016.02.028

431. Wouters MM, Vicario M, Santos J. Th e role of mast cells in functional GI disorders. Gut. 2016; 65:155–68; PMID: 26194403; doi.org/10.1136/gutjnl-2015–309151

432. Sinagra E, Morreale G, Mohammadian G, et al. New the ra peutic perspectives in irritable bowel syndrome: Targeting low-grade infl ammation, immunoneuroendocrine axis, motility, secretion and beyond. World J Gastroenterol. 2017;23(36):6593–627. doi: 10.3748/ wjg.v23.i36.6593

433. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019. 68(8):1516– 1526 doi: 10.1136/gutjnl-2019–31842

434. Vermette D, Hu P, Canarie MF, Funaro M, Glover J, Pierce RW. Tight junction structure, function, and assessment in the critically ill: a systematic review. Intensive Care Med Exp. 2018 Sep 26;6(1):37. doi: 10.1186/ s40635–018–0203–4

435. Al- Sadi R., Guo S., Ye D., Rawat M., Ma T. TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway. Am J Pathol. 2016 May; 186(5): 1151–1165. doi: 10.1016/j.ajpath.2015.12.016

436. Johansson ME, Sjövall H, Hansson GC. Th e gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):352–61. doi: 10.1038/nrgastro.2013.35

437. D’Antongiovanni V, Pellegrini C, Fornai M, et al. Intestinal epithelial barrier and neuromuscular compartment in health and disease. World J Gastroenterol. 2020;26(14):1564‐1579. doi:10.3748/wjg.v26.i14.1564

438. Tack J, Masuy I, Van Den Houte K, Wauters L, Schol J, Vanuytsel T, Vandenberghe A, Carbone F. Drugs under development for the treatment of functional dyspepsia and related disorders. Expert Opin Investig Drugs. 2019 Oct;28(10):871–889. doi: 10.1080/13543784.2019.1673365

439. Дичева Д. Т., Андреев Д. Н., Ульянкина Е. В. Синдром перекреста ГЭРБ, функциональной диспепсии и СРК: патогенетические связи и подходы к терапии // Эффективная фармакотерапия. 2019. Т. 15. № 36. С. 64–70. doi 10.33978/2307–3586–2019–15– 36–64–70.

440. Egloff N, Beer C, Gschossmann JM, Sendensky A, von Känel R. Multimodale Therapie funktioneller Erkrankungen des Verdauungstraktes [Multimodal therapy of functional gastrointestinal disorders]. Praxis (Bern 1994). 2010 Apr14;99(8):487–93. German. doi: 10.1024/1661–8157/a000095.

441. Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А., Трухманов А. С., Абдулхаков Р. А., Але ксеенко С. А., Дехнич Н. Н., Козлов Р. С., Кляритская И. Л., Курилович С. А., Осипенко М. Ф., Симаненков В. И., Хлынов И. Б. Лечение инфекции helicobacter pylori: мейнстрим и новации (обзор литературы и резолюция экспертного совета российской гастроэнтерологической ассоциации 19 мая 2017 г.) //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017. Т. 27. № 4. С. 4–21.

442. Горячева Е. Е., Алексеева Щ. П. Касимова Л. Н. Приверженность лечению у пациентов с гастроэнтерологической патологией: роль отдельных факторов Казанский медицинский журнал, 2016 г., том 97, № 1, С. 31–37 doi: 10.17750/KMJ2016–31.

443. Симаненков В. И., Сундукова З. Р., Соловьева О. И. Возможности мультитаргетной терапии больных с синдромом раздраженного кишечника. Consilium Medicum. 2017; 19 (8.2. Гастроэнтерология): 37–44. doi: 10.26442/2075–1753_19.8.2.37–44.

444. Карева Е. Н., Сереброва С. Ю. Медикаментозное лечение нарушений моторики желудка–проблемы, пути решения, достижения. Экспериментальная и клиническая гастроэнтерология, № 7, 2017. 167–183.

445. Долгалёв И. В. Клинические примеры применения ингибитора протонной помпы и прокинетика у первичных пациентов с симптомами диспепсии. Трудный пациент, 2020, № 5, том 18, 10–17.

446. Лялюкова Е. А., Батищева Г. А., Визе- Хри пу нова М.А., Лапина Е. Д., Лялюкова А. С., Онучина Е. В., Позднякова О. Ю., Чернышева Е. Н., Якоб О. В., Павлова Н. В. Синдром диспепсии в первичном звене здравоохранения: клинические варианты, тактика ведения пациентов. Трудный пациент № 6–7, ТОМ 17, 2019. 38–46. doi: 10.24411/2074–1995– 2019–10051.

447. Lee HT, Kim BJ. Trimebutine as a modulator of gastrointestinal motility. Arch Pharm Res. 2011 Jun;34(6):861–4. doi: 10.1007/s12272–011–0600–7

448. Roman FJ, Lanet S, Hamon J, Brunelle G, Maurin A, Champeroux P, Richard S, Alessandri N, Gola M. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Th er. 1999 Jun;289(3):1391–7.

449. Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol. 2019 Sep;65(3):229–238. doi: 10.23736/S1121–421X.19.02567–4.

450. Kountouras J, Gavalas E, Doulberis M, Polyzos SA, Papaeft hy miou A, Touloumtzi M, Vardaka E, Kountouras K, Papanikolopoulou K, Katsinelos P. The Eff ect of trimebutine and/or Helicobacter pylori Eradi cation, on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders. J Neurogastroenterol Motil. 2019 Jul1;25(3):473–474. doi: 10.5056/jnm19033

451. Ивашкин В. Т., Полуэктова Е. А., Рейхарт Д. В., Шифрин О. С., Бениашвили А. Г., Ляшенко О. С., Белостоцкий А. В. Эффективность наиболее часто назначаемых групп препаратов у пациентов с функциональными расстройствами желудочнокишечного тракта – синдромом функциональной диспепсии и синдромом раздраженного кишечника (Результаты наблюдательного исследования). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):14–23. doi: 10.22416/1382–4376–2016–26–4–14–23

452. Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019;1125:121–137. doi: 10.1007/5584_2018_321

453. Ritchie M, Romanuk T. 2012. A Meta- Analysis of Probiotic Efficacy for Gastrointestinal. Diseases PLoS One. 7(4): e34938.

454. Verhoog S, Taneri PE, Roa Díaz ZM, et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019;11(7):1565. Published 2019 Jul 11. doi:10.3390/nu11071565

455. Koretz RL. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Am J Gastroenterol. 2018 Aug;113(8):1125–1136. doi: 10.1038/s41395–018–0138–0

456. Quigley EMM. Prebiotics and Probiotics in Digestive Health. Clin Gastroenterol Hepatol. 2019 Jan;17(2):333– 344. doi: 10.1016/j.cgh.2018.09.028

457. Соловьева О. И., Симаненков В. И., Суворов А. Н., Ермоленко Е. И., Шумихина И. А., Свиридо Д.А Использование пробиотиков и аутопробиотиков в лечении синдрома раздраженной толстой кишки/.//Экспериментальная и клиническая гастроэнтерология. 2017. № 7 (143). 115–120.

458. Dale HF, Rasmussen SH, Asiller ÖÖ, Lied GA. Probiotics in Irritable Bowel Syndrome: An Up-to- Date Systematic Review. Nutrients. 2019 Sep 2;11(9):2048. doi: 10.3390/ nu11092048

459. Lapina TL, Trukhmanov AS. Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice. Dig Dis. 2017;35 Suppl 1:30–35. doi: 10.1159/000485411

460. Malfertheiner P. STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders. Dig Dis. 2017;35 Suppl 1:25–29. doi: 10.1159/000485410

461. Allescher HD, Wagner H. STW 5/Iberogast: multitarget action for treatment of functional dyspepsia and irritable bowel syndrome]. Wien Med Wochenschr. 2007;157(13–14):301–7. German. doi: 10.1007/s10354– 007–0429–3

462. Kim YS, Kim JW, Ha NY, Kim J, Ryu HS. Herbal Th erapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication. Front Psychiatry. 2020 Jul 10;11:601. doi: 10.3389/fpsyt.2020.00601

463. Xiong N, Duan Y, Wei J, Mewes R, Leonhart R. Antidepressants vs. Placebo for the Treatment of Functional Gastrointestinal Disorders in Adults: A Systematic Review and Meta- Analysis. Front Psychiatry. 2018 Dec 4;9:659. doi:10.3389/fpsyt.2018.00659

464. Rekka E, Chrysselis M, Siskou I, Kourounakis A. Synthesis of new azulene derivatives and study of their effecton lipid peroxidation and lipoxygenase activity. Chem Pharm Bull (Tokyo). 2002; 50: 904–907. doi: 10.1248/cpb.50.904

465. Yano S, Horie S, Wakabayashi S, Mochizuki S, Tomiya ma A, Watanabe K. Increasing effect of sodium 3-ethyl-7- isopropyl-1-azulenesulfonate 1/3 hydrate (KT1–32), a novel antiulcer agent, on gastric mucosal blood fl ow in anesthetized. Res Commun Chem Pathol Pharmacol. 1990; 70: 253–256.

466. Bergmann JF, Simoneau G, Chantelair G, Caulin C, Segrestaa JM. Use of dimethicone to reduce the fall in gastric potential diff erence induced by bile salts. Eur J Clin Pharmacol. 1989; 36: 379–381. doi: 10.1007/ BF00558299

467. Ogilvie AL, Atkinson M. Does dimethicone increase the effi cacy of antacids in the treatment of refl ux oesophagitis? J R Soc Med. 1986; 79: 584–587.

468. Leplège A, Mackenzie- Schliacowsky N, Eacute Cosse E, Ruszniewski P. Quality of life scale and impact of a topical treatment on symptoms of gastro- esophageal refl ux without severe esophagitis. Gastroenterol Clin Biol. 2005; 29: 676–681. doi: GCB-6–7–2005–29–6–7–0399– 8320–101019–200514443

469. Ruszniewski P. Etude multicentrique de phase III, randomisé en double aveugle, contrôlé versus placebo, de leffi cacité et de la tolérance du gaiazulene associe à la diméticone (Pepsane®) dans le traitement des symptômes de refl ux gastro- sophagien non compliqué. Act Med Int Gastroenterologie. 2003; 17 (suppl 1): 1–10.

470. Zourabichivili O. Stomalene et pathologie gastroesophagiene. Med Chi Dig. 1986; 15: 217–220.

471. Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Eff ect of Antidepressants and Psychological Th erapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta- Analysis. Am J Gastroenterol. 2019. Jan;114(1):21–39. doi: 10.1038/s41395–018–0222–5

472. Törnblom H, Drossman DA. Psychotropics, Antide pressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. Curr Gastroenterol Rep. 2018 Nov 5;20(12):58. doi: 10.1007/s11894–018–0664–3

473. Звяглова М. Ю., Князев О. В., Парфенов А. И. Ребами пид: перспективы применения в гастроэнтерологии и не только. Терапевтический архив. 2020; 92 (2): 104–111. doi: 10.26442/00403660.2020.02.000569.

474. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Eff ect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014 Dec;29 Suppl 4:20–4. doi: 10.1111/ jgh.12769

475. Симаненков ВИ, Бакулина НВ, Филь ТС, Хубиева А Х. Оценка эффективности эрадикации Н. pylori при добавлении к схеме лечения цитопротективного препарата ребамипид: результаты исследования БАСТИОН // Фарматека Гастроэнтерология/ Гепатология: 2017,2; 65–71.

476. Adachi K, Furuta K, Miwa H, Oshima T, Miki M, Komazawa Y, Iwakiri K, Furuta T, Koike T, Shimatani T, Kinoshita Y. A study on the effi cacy of rebamipide for patients with proton pump inhibitor- refractory non-erosive refl ux disease. Dig Dis Sci. 2012 Jun;57(6):1609–17. doi: 10.1007/s10620–012–2087–6

477. Ивашкин В. Т., Трухманов А. С., Гоник М. И. При менение ребамипида в лечении гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2020; 92 (4): 98–104. doi: 10.26442/00403660.2020.04.000568.

478. Shibli F, Kitayama Y, Fass R. Novel Therapies for Gastroesophageal Refl ux Disease: Beyond Proton Pump Inhibitors. Curr Gastroenterol Rep. 2020 Mar 17;22(4):16. doi: 10.1007/s11894–020–0753-y

479. Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T, Hori K, Matsumoto T, Sato N. Effect of a gastro- protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double- blind placebo- controlled study in Japan. J Gastroenterol Hepatol. 2006 Dec;21(12):1826–31. doi:10.1111/j.1440–1746.2006.04446.x

480. Pittayanon R, Leelakusolvong S, Vilaichone RK, et al. Th ailand Dyspepsia Guidelines: 2018. J Neuro gastroenterol Motil. 2019 Jan 31;25(1):15–26. doi: 10.5056/ jnm18081

481. Ivanov S. V. Irritable bowel syndrome. Psychiatry and psychopharmacotherapy. 2000; 2: 109–111. (in Russ.) Иванов С. В. Синдром раздраженной толстой кишки. Психиатрия и психофармакотерапия. 2000;2:109–111.

482. Маев И. В., Бордин Д. С., Ерёмина Е. Ю. и др. Cиндром раздраженного кишечника. Современные аспекты эпидемиологии, патогенеза и лечения (обзор). Экспериментальная и клиническая гастроэнтерология. 2018;158(10): 68–73. DOI: 10.31146/1682– 8658-ecg-158–10–68–73

483. Törnblom H., Drossman D. A. Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. Current gastroenterology reports. 2018; 20(12): 58. Doi: 10.1007/s11894–018– 0664–3

484. Lu Y., Chen M., Huang Z. et al. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta- Analysis. PloS one. 2016; 11(6): e0157798. Doi: 10.1371/journal.pone.0157798

485. Talley NJ, Locke GR, Saito YA et al. Eff ect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149(2):340–9 e2.

486. Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome foundation working team report. Gastroenterology. 2018;154(4):1140–71 e1.

487. Jiang S. M., Jia L., Liu J. et al. Benefi cial eff ects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World journal of gastroenterology. 2016; 22(22): 5260–5266. Doi: 10.3748/wjg.v22.i22.5260

488. Tack J., Ly H. G., Carbone F. et al. Effi cacy of Mir taza pine in Patients With Functional Dyspepsia and Weight Loss. Clinical gastroenterology and hepatology: the offi cial clinical practice journal of the American Gastroenterological Association. 2016; 14(3): 385–392. e4. doi: 10.1016/j.cgh.2015.09.043

489. Khalilian A., Ahmadimoghaddam, D., Saki, S. et al. A randomized, double- blind, placebo- controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. BioPsychoSocial Med. 2021; 15: 3. Doi: 10.1186/s13030– 021–00205–2

490. Balakina I. V., Mironova T., Golovanova E. N. Effi cacy and safety of valdoxan in patients with irritable bowel syndrome. Zhurnal nevrologii i psikhiatrii imeni S. S. Korsakova. 2014; 114(4): 90–92.

491. Seddighnia A., Tadayon Najafabadi B., Ghamari, K. Vortioxetine eff ects on quality of life of irritable bowel syndrome patients: A randomized, double- blind, placebo- controlled trial. Journal of clinical pharmacy and therapeutics. 2020; 45(1): 97–104. Doi: 10.1111/ jcpt.13032

492. Smyla N., Stephanie E., Stephanie W. et al. Amisulpride for the prevention and treatment of postoperative nausea and vomiting: A quantitative systematic review (meta-analysis). Drugs of the Future. 2019; 44(6):453.

493. Rasheed N, Ahmad A, Singh N et al. Diff erential response of A 68930 and sulpiride in stress- induced gastric ulcers in rats. Eur J Pharmacol. 2010; 643 (1): 121–8.

494. El- Reshaid K, Al- Bader S. New regimen for treatment of irritable bowel syndrome with emphasis on Sulpride as the sole maintenance therapy. JDDT. 2019; 9(5):154–7.

495. Warnez S., Alessi- Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC psychiatry. 2014; 14: 102. Doi: 10.1186/1471–244X-14– 102

496. Gupta N., Puri S., Kumar V. et al. Olanzapine in the Treat ment of Refractory Nausea and Vomiting in Palliative Care Settings. Indian journal of palliative care. 2018; 24(3): 372–374. Doi: 10.4103/IJPC.IJPC_30_18

497. Grover M, Dorn SD, Weinland SR, et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci. 2009;54:1284–91.

498. Jimenez X. F., Sundararajan T., Covington, E. C. A Systema tic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/ Migraine. Th e Clinical journal of pain. 2018; 34(6): 585– 591. Doi: 10.1097/AJP.0000000000000567

499. Tack J., Janssen P., Masaoka T. et al. Effi cacy of buspirone, a fundus- relaxing drug, in patients with functional dyspepsia. Clinical gastroenterology and hepatology: the offi cial clinical practice journal of the American Gastroenterological Association. 2012; 10(11): 1239–1245. Doi: 10.1016/j.cgh.2012.06.036

500. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Th erapeutic advances in drug safety. 2014; 5(1): 38–56. Doi: 10.1177/2042098613505614

501. Shafi gh- Ardestani M. H., Karami- Horestani M., Emami B. et al. Evaluating the Eff ect of Oral Gabapentin on the Improvement of Gastrointestinal Symptoms in Patients with Functional Dyspepsia Resistant to Conventional Treatments. Advanced biomedical research. 2019; 8: 53. Doi: 10.4103/abr.abr_234_18

502. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second- generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218–25.

503. Balon R., Sonino N., & Rafanelli C. Benzodiazepines’ Role in Managing Gastrointestinal Disorders. Psychotherapy and psychosomatics. 2021; 90(2): 81–84. Doi: 10.1159/000510686 505. Matysiak- Budnik T., et al., Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Th er. 2003; 18 (Suppl. 1): 55–62.

504. Tarnawski A. S., et al. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?, Dig Dis Sci. 2004 Feb;49(2):202–9.

505. Tanigawa T, Watanabe T, Otani K, Nadatani Y, et al. Rebamipide inhibits indomethacin- induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha- defensin 5. Eur J Pharmacol. 2013; 704: 64–69. doi: 10.1016/j. ejphar.2013.02.010. PMID: 23428631.

506. Kurata S., et al., Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015 Jan; 56(1): 20–27. doi: 10.3164/jcbn.14–67

507. Su Jin Hong, et al. Th e Benefi ts of Combination Th erapy with Esomeprazole and Rebamipide in Symptom Improvement in Refl ux Esophagitis: An International Multicenter Studyю Gut Liver. 2016 Nov; 10(6): 910–916.

508. Gweon TG, Park JH, Kim BW, et al. Additive Eff ects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro- Esophageal Reflux Disease. Gut Liver. 2018;12(1):46–50. doi:10.5009/gnl17078

509. Adachi K., et al., A study on the effi cacy of rebamipide for patients with proton pump inhibitor- refractory nonerosive refl ux disease Dig Dis Sci. 2012 Jun;57(6):1609–17.

510. Maradey- Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20 (1):6–16. doi:10.5056/ jnm.2014.20.1.6

511. Sawada A, Fujiwara Y, Sifrim D. Belching in Gastroesophageal Refl ux Disease: Literature Review. J Clin Med. 2020 Oct 20;9(10):3360. doi: 10.3390/ jcm9103360. PMID: 33092195; PMCID: PMC7590068.

512. Taki M. et al., Duodenal low-grade infl ammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol Motil. 2019 Feb 20: e13576.

513. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Effi cacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta- Analysis. Dig Dis Sci. 2018 May;63(5):1250–1260. doi: 10.1007/ s10620–017–4871–9. Epub 2017 Dec 1. PMID: 29192375.

514. Rangan V, Cremonini F. Rebamipide in Functional and Organic Dyspepsia: Sometimes the Best Off ense Is a Good Defense. Dig Dis Sci. 2018 May;63(5):1089–1090. Doi:10.1007/s10620–018–4974-y. PMID: 29464582

515. Pimentel- Nunes P et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr; 51:365. Doi: org/10.1055/a-0859–1883

516. Seo GH, Lee H. Chemopreventive Eff ect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221– 228. doi: 10.1159/000495288. Epub 2018 Nov 28. PMID: 30485855.

517. Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, Kim SE, Jung K, Kim JS, Park JK, Bang KB, Baeg MK, Shin JE, Shin CM, Lee JY, Lim HC; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020 Jan 30;26(1):29–50. doi: 10.5056/jnm19209. PMID: 31917913; PMCID: PMC6955183.

518. Lai Y, Zhong W, Yu T, et al. Rebamipide Promotes the Regeneration of Aspirin- Induced Small- Intestine Mucosal Injury through Accumulation of β- Catenin. PLoS One. 2015;10(7): e0132031. Published. 2015 Jul 2. doi:10.1371/journal.pone.0132031

519. Jang H, Park S, Lee J, et al. Rebamipide alleviates radiation- induced colitis through improvement of goblet cell diff erentiation in mice. J Gastroenterol Hepatol. 2018 Apr;33(4):878–886. doi: 10.1111/jgh.14021. Epub 2018 Jan 19. PMID: 29047150.

520. Парфенов А. И., Белостоцкий Н. И., Хомерики С. Г., и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование // Терапевтический архив. – 2019. –Т. 91. –№ 2. –C. 25– 31. doi: 10.26442/00403660.2019.02.000123

521. Takagi T, Naito Y, Uchiyama K, et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011;17(33):3802–9. doi:10.3748/wjg.v17.i33.3802

522. Цуканов В. В., Онучина Е. В., Васютин А. В., Тонких Ю. Л. Опыт применения урсодезоксихолевой кислоты для растворения желчных камней. Медицинский совет. 2019;(21):160–165. doi: 10.21518/2079–701X-2019–21–160–165.

523. Гаус О. В., Ахмедов В. А. Прогнозирование эффективности пероральной литолитической терапии у больных с желчнокаменной болезнью, ассоциированной с метаболическим синдромом // Современные проблемы науки и образования. – 2016. – N 5. – Р. 41–47.

524. Марцевич С. Ю., Кутишенко Н. П., Дроздова Л. Ю., Лерман О. В., Невзорова В. А., Резник И. И., Шавкута Г. В., Яхонтов Д. А. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС). Рациональная Фармакотерапия в Кардиологии. 2014;10(2):147–152. Doi: 10.20996/1819–6446–2014– 10–2–147–152